EP2589391B1 - Bacterial cell-derived microvesicles for use in a method of treating cancer - Google Patents
Bacterial cell-derived microvesicles for use in a method of treating cancer Download PDFInfo
- Publication number
- EP2589391B1 EP2589391B1 EP11801165.9A EP11801165A EP2589391B1 EP 2589391 B1 EP2589391 B1 EP 2589391B1 EP 11801165 A EP11801165 A EP 11801165A EP 2589391 B1 EP2589391 B1 EP 2589391B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- microvesicles
- derived
- drug
- cancer
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001580 bacterial effect Effects 0.000 title claims description 142
- 206010028980 Neoplasm Diseases 0.000 title claims description 105
- 201000011510 cancer Diseases 0.000 title claims description 82
- 238000000034 method Methods 0.000 title description 38
- 239000003814 drug Substances 0.000 claims description 118
- 241000894006 Bacteria Species 0.000 claims description 93
- 239000000126 substance Substances 0.000 claims description 93
- 229940079593 drug Drugs 0.000 claims description 88
- 239000002158 endotoxin Substances 0.000 claims description 75
- 231100000419 toxicity Toxicity 0.000 claims description 68
- 230000001988 toxicity Effects 0.000 claims description 68
- 230000000694 effects Effects 0.000 claims description 64
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 230000001225 therapeutic effect Effects 0.000 claims description 50
- 230000001093 anti-cancer Effects 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 27
- 239000002246 antineoplastic agent Substances 0.000 claims description 25
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 23
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 21
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 241000192125 Firmicutes Species 0.000 claims description 10
- 238000011275 oncology therapy Methods 0.000 claims description 9
- 102000004889 Interleukin-6 Human genes 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 108010093965 Polymyxin B Proteins 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 229940100601 interleukin-6 Drugs 0.000 claims description 8
- 229920000024 polymyxin B Polymers 0.000 claims description 8
- 229960005266 polymyxin b Drugs 0.000 claims description 8
- 230000011664 signaling Effects 0.000 claims description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 231
- 210000001519 tissue Anatomy 0.000 description 91
- 241000588724 Escherichia coli Species 0.000 description 83
- 230000002829 reductive effect Effects 0.000 description 61
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 58
- 239000002953 phosphate buffered saline Substances 0.000 description 58
- 229920006008 lipopolysaccharide Polymers 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 41
- 208000029742 colonic neoplasm Diseases 0.000 description 35
- 239000012528 membrane Substances 0.000 description 35
- 206010009944 Colon cancer Diseases 0.000 description 34
- 239000000243 solution Substances 0.000 description 32
- 229940124597 therapeutic agent Drugs 0.000 description 30
- 239000002105 nanoparticle Substances 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 23
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 238000003745 diagnosis Methods 0.000 description 21
- 239000000725 suspension Substances 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 239000002502 liposome Substances 0.000 description 17
- 210000000170 cell membrane Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 230000005907 cancer growth Effects 0.000 description 14
- 238000010171 animal model Methods 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 210000001072 colon Anatomy 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 229960004679 doxorubicin Drugs 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 210000003462 vein Anatomy 0.000 description 11
- 108010052285 Membrane Proteins Proteins 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000008685 targeting Effects 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 239000002260 anti-inflammatory agent Substances 0.000 description 8
- 210000001772 blood platelet Anatomy 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000005199 ultracentrifugation Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000001125 extrusion Methods 0.000 description 6
- -1 for example Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 5
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 description 5
- 101710116435 Outer membrane protein Proteins 0.000 description 5
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 5
- 239000004037 angiogenesis inhibitor Substances 0.000 description 5
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 108091006047 fluorescent proteins Proteins 0.000 description 5
- 102000034287 fluorescent proteins Human genes 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 239000003154 D dimer Substances 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- 108700006385 OmpF Proteins 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 4
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 108010052295 fibrin fragment D Proteins 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000002096 quantum dot Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 108091005703 transmembrane proteins Proteins 0.000 description 4
- 102000035160 transmembrane proteins Human genes 0.000 description 4
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 101100021843 Shigella flexneri lpxM1 gene Proteins 0.000 description 3
- 101100021844 Shigella flexneri lpxM2 gene Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 229940124466 diagnostic for cancer Drugs 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 238000001997 free-flow electrophoresis Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 101150060640 lpxM gene Proteins 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000002525 ultrasonication Methods 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 102000018897 Membrane Fusion Proteins Human genes 0.000 description 2
- 108010027796 Membrane Fusion Proteins Proteins 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 241000607149 Salmonella sp. Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000030429 T-helper 17 type immune response Effects 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 239000002041 carbon nanotube Substances 0.000 description 2
- 229910021393 carbon nanotube Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 201000011061 large intestine cancer Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000010297 mechanical methods and process Methods 0.000 description 2
- 230000005226 mechanical processes and functions Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000000575 proteomic method Methods 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010030317 Macrophage-1 Antigen Proteins 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700028353 OmpC Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 241000385732 bacterium L Species 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 1
- 229940071238 n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine Drugs 0.000 description 1
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YNQYZBDRJZVSJE-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl 2,3-di(octadecanoyloxy)propyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC YNQYZBDRJZVSJE-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229950008396 ulobetasol propionate Drugs 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Definitions
- the present invention relates to certain bacterial cell-derived spontaneously shedding microvesicles for use in the treatment of cancer.
- Vautier reported the apparent cure of cancer in patients who concurrently suffered from gas gangrene caused by the infection of the anaerobic bacterium Clostridium perfringens. Since then, extensive studies have been undertaken on the deliberate injection of various bacteria including Salmonella typhimurium in addition to Clostridium , with the concept of bacteria-mediated cancer therapy. As a cancer grows over a certain size (approximately 1 mm 3 ), it undergoes an undersupply of oxygen from surrounding vessels, with the formation of hypoxia within the cancer tissue. The cancer tissue in a hypoxia state provides an environment in which anaerobic bacteria are readily likely to proliferate while they might attack surrounding cancer cells to necrosis using various toxins and/or through unknown mechanisms.
- bacteria are transformed to express anticancer proteins, or are used to deliver a plasmid carrying an anticancer protein gene to a cancer tissue.
- auxotrophic mutants, spores, and attenuated bacteria have also been tried for cancer therapy.
- the use of bacteria in cancer therapy always has the risk of bacterial proliferation in normal tissues or organs surrounding the cancer mass.
- Gram-positive bacteria such as Escherichia coli , Neisseria meningitidis , Pseudomonas aeruginosa , and Shigella flexneri , are known to spontaneously shed microvesicles from the outer membrane.
- the Gram-negative bacterial cell-derived shedding microvesicles are known as outer membrane vesicles typically consisting of a lipid bilayer.
- Bacterial cell-derived shedding microvesicles serve as an information carrier which plays a role in the transport of proteins or genetic materials between homogeneous cells and in cell-to-cell signaling, and contributes to the removal of competitive organisms or the survival of bacteria. In addition, the shedding microvesicles deliver toxins to hosts, thus accounting, in part, for the etiology of bacterial diseases.
- shedding microvesicles were found in the blood of patients who died of severe sepsis suggest that shedding microvesicles play an important role in the pathology of sepsis, which is characterized by systemic inflammation. This is also supported by the research finding that bacterial cell-derived shedding microvesicles stimulate host cells to secrete inflammatory cytokines and coagulants.
- Gram-positive bacteria including Bacillus subtilis and Staphylococcus aureus produce shedding microvesicles, which was first found by the present inventors. However, there is a need for more information on components or functions of Gram-positive bacterial cell-derived shedding microvesicles.
- Microvesicles that spontaneously shed from various bacteria species have been isolated and observed. Typically, shedding microvesicles are isolated from cell cultures by filtration or ultracentrifugation. In addition, it is known that the production of shedding microvesicles can be controlled with an antibiotic such as gentamicin. Particularly, there is a suggestion that shedding microvesicles prepared by treatment with a detergent might be applied as a vaccine against the infection of N. meningitidis , a bacterial pathogen. However, the capacity of these production methods is seriously limited.
- WO 87/07503 discloses a biologic response modifier substantially free of endotoxin, intact cells, cell walls, and cell membrane fragments, which comprises natural membrane vesicles and ribosomes in a suspending buffer.
- WO 91/12813 discloses a method for treating tumors in a mammalian patient by administering a combination of a chemotherapeutic agent and a biological response modifier, which comprises natural membrane vesicles and ribosomes.
- EP 2 027 865 discloses a liposome having a lipid membrane containing a bacterial cell component.
- GABRI ET AL, CLINICAL CANCER RESEARCH, vol. 12, no. 23,(2006), pages 7092-7098 discloses antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
- the present invention provides bacterial cell-derived spontaneously shedding microvesicles for use in the treatment of cancer, wherein
- the bacteria used in the present invention may come from Gram-positive or Gram-negative bacteria, and may be native or genetically transformed.
- a nanoparticle therapeutic agent may be loaded with such a drug and/or cell therapeutic agent.
- microvesicles according to claim 1 may be administered simultaneously/sequentially together with a drug that neutralizes the toxicity of endotoxin of the microvesicles, a drug that enhances anticancer activity, a nanoparticle therapeutic agent loaded with such a drug and/or cell therapeutic agent.
- the bacterial cell-derived microvesicles may be microvesicles that are spontaneously shed from bacteria, or artificial microvesicles.
- a method for preparing shedding microvesicles for the treatment or diagnosis of cancer may comprise the following steps: adding a drug to a suspension of bacteria or transformed bacteria to give a bacterial suspension containing the drug; and isolating shedding microvesicles loaded with the drug from the bacterial suspension.
- a method for preparing shedding microvesicles for the treatment or diagnosis of cancer may comprise the following steps: isolating shedding microvesicles from a culture of bacteria or transformed bacteria; and incubating a suspension of the isolated microvesicles with a drug. This method may further comprise isolating shedding microvesicles loaded with the drug for the treatment or diagnosis of cancer.
- a method for preparing artificial microvesicles for the treatment or diagnosis of cancer may comprise the following steps: mixing a suspension of bacteria or transformed bacteria with a drug to give a bacterial suspension containing the drug; constructing artificial microvesicles using a process selected from the group consisting of extrusion, ultrasonication, disruption, homogenization, freeze-thawing, electroporation, mechanical degradation, and chemical treatment of the bacterial suspension; and isolating the artificial microvesicles.
- a method for preparing artificial microvesicles for the treatment or diagnosis of cancer may comprise the following steps: constructing artificial microvesicles using a process selected from the group consisting of extrusion, ultrasonication, disruption, homogenization, freeze-thawing, electroporation, mechanical degradation, and chemical treatment of suspension of bacteria or transformed bacteria; and isolating the artificial microvesicles; and incubating a suspension of the isolated microvesicles with a drug.
- This method may further comprise isolating artificial microvesicles loaded with the drug for the treatment or diagnosis of cancer from the bacterial suspension.
- the preparation method may further comprise sterilizing the shedding or artificial microvesicles for the treatment or diagnosis of cancer using a process selected from the group consisting of antibiotic treatment, UV exposure, gamma ray exposure, and filtration.
- composition comprising bacterial cell-derived microvesicles loaded with a drug therapeutic or diagnostic for cancer.
- composition comprising bacterial cell-derived microvesicles loaded with a drug therapeutic or diagnostic for cancer, the bacterial cell being transformed to target cancer cells or tissues.
- kits for the diagnosis of a disease comprising bacterial cell-derived microvesicles loaded with a substance diagnostic for the disease.
- the invention provides bacterial cell-derived spontaneously shedding microvesicles for use in the treatment of cancer, wherein
- the microvesicles according to the claims may be loaded with a protein as an active ingredient.
- the protein may be derived from Gram-negative or Gram-positive bacteria.
- the microvesicles according to the claims may be loaded with a nucleic acid as an active ingredient.
- the nucleic acid may be derived from Gram-negative or Gram-positive bacteria.
- the microvesicles according to the claims may be loaded with a lipid as an active ingredient.
- the lipid may be derived from Gram-negative or Gram-positive bacteria.
- the microvesicles according to the claims may be loaded with two or more components selected from a protein, a nucleic acid and a lipid as active ingredients. Also disclosed is the use of a nanoparticle therapeutic agent reconstituted with a protein in treating cancer, the protein being a component of bacterial cell-derived microvesicles.
- nanoparticle therapeutic agent loaded with a nucleic acid in treating cancer, the nucleic acid being a component of bacterial cell-derived microvesicles.
- nanoparticle therapeutic agent reconstituted with a lipid in treating cancer, the lipid being a component of bacterial cell-derived microvesicles.
- nanoparticle therapeutic agent loaded or reconstituted with two or more components of bacterial cell-derived microvesicles in treating cancer.
- proteins present as one of the components of the bacterial cell-derived microvesicles, include water-soluble proteins, lipid-soluble proteins, or membrane proteins, but are not limited thereto.
- the nucleic acids may include DNA and RNA, but are not limited thereto.
- the bacterial cell-derived spontaneously shedding microvesicles for use in accordance with the present invention can be applied to the treatment of cancer, with a decrease in the side effects of conventional drugs, whereby the agony and inconvenience of the patient in the course of treatment can be reduced.
- Conventional anticancer agents act non-specifically on proliferating cells, causing side effects upon exertion of their cytotoxicity on normal cells.
- conventional administration methods allow anticancer agents to be delivered to not only cancer cells or tissues, but also non-cancerous organs, thus causing significant side effects.
- cancer in elderly persons is rising as a social problem.
- Abnormality of immune functions which lose the capacity of controlling the growth of cancer mainly accounts for the onset and progression of cancer, but there are only rare cases in which cancer is treated by enhancing the defense mechanism of effectively suppressing the growth of cancer.
- microvesicles for use according to the present invention can be used in effectively suppressing the growth of cancer.
- microvesicles derived from bacterial cells according to the claims, whether or not transformed can be directed towards cancer vessels, cells or tissues, thus minimizing the adverse effects resulting from the erroneous targeting of microvesicles.
- a drug such as an anticancer agent, an anti-inflammatory agent, etc.
- the microvesicles can deliver the drug accurately and thus maximizes the therapeutic effect of the drug, while neither being directed toward off-target cells, nor causing side effects.
- microvesicles that are reduced in toxicity and improved in therapeutic capacity can be prepared using a genetic, chemical or mechanical process disclosed herein.
- Another advantage of the bacterial cell-derived spontaneously shedding microvesicles for use according to the present invention is the mass production thereof, together with the applicability thereof to a wide spectrum of subjects.
- any targeting molecule, therapeutic substance or diagnostic substance may be loaded on or within bacterial cell-derived microvesicles without purification.
- the loaded substances can perform their inherent functions effectively.
- the present invention provides bacterial cell-derived spontaneously shedding microvesicles for use in the treatment of cancer, wherein
- the bacteria useful in the present invention may be Gram-negative or Gram-positive.
- Exemplary among the Gram-negative bacteria are E. coli , Pseudomonas aeruginosa , and Salmonella sp.
- Examples of the Gram positive bacteria include Staphylococcus aureus and Lactobacillus acidophilus, but are not limited thereto.
- bacteria refers to naturally occurring bacteria or transformed bacteria. More specifically, the term “transformed bacteria,” as used herein, is intended to include, but is not limited to, bacteria that have been transformed to have reduced toxicity, for example, have a modified endotoxin gene; bacteria that have been transformed to express a substance necessary for targeting cells or tissues of interest, for example cancer vessels, cancer tissues or cancer cells; and bacteria that have been transformed to express a substance necessary for cell membrane fusion with a target cell, therapy and/or diagnosis of a disease of interest; and bacteria that have been transformed to both upregulate a substance of interest and downregulate a substance of interest.
- the bacteria may be transformed two or more times by treating the cells with a substance, or by introducing a foreign gene into the cells.
- the bacteria may be transformed to downregulate at least one protein involved in toxicity.
- the transformed bacteria may be adapted to express one or more substances selected from the group consisting of, but not limited to, a cell adhesion molecule, an antibody, a targeting protein, a cell membrane fusion protein, and a fusion protein thereof.
- bacterial cell-derived microvesicles is limited to “shedding microvesicles”, which are spontaneously secreted from bacteria. Excluded from the invention are “artificial microvesicles,” which are artificially synthesized using a genetic, chemical or mechanical process.
- bacterial cell-derived microvesicles refers to sub-cell sized vesicles, the interior of which is separated from the outside environment only by a lipid bilayer membrane and which have plasma membrane lipids, plasma membrane proteins, nucleic acid, and bacterial components.
- spontaneously shedding microvesicles for use according to the present invention may be constructed using one of the following illustrative, non-limiting methods.
- the bacterial cell-derived microvesicles according to the claims may further comprise components in its membrane other than those derived from the cell membrane of the bacteria.
- the components other than those derived from the cell membrane may include targeting molecules, fusogens, which are necessary for membrane fusion with target cells, cyclodextrins, and polyethylene glycol.
- the components other than those derived from the cell membrane may be added using a variety of methods, including chemical modification of cell membranes.
- membrane components of the bacterial cell-derived microvesicles may be chemically modified with thiol (-SH) or amine (-NH 2 ) groups or by chemically bonding polyethylene glycol to the membrane.
- the method for preparing bacterial cell-derived microvesicles disclosed herein may further comprise the chemical modification of membrane components.
- the microvesicles according to the claims may comprise a drug that functions to neutralize the toxicity of endotoxin of the microvesicles themselves.
- the drug may be loaded to the microvesicles.
- the drug may function to suppress the toxicity of endotoxins, and may be polymyxin B.
- the microvesicles according to the claims may further comprise a drug that enhances anticancer activity.
- the drug may be loaded to the microvesicles.
- the drug useful in the present invention includes a drug suppressive of the immune response of Th17 (T helper 17), a drug suppressive of the production or activity of interleukin 6 (IL-6), a drug suppressive of the production or activity of vascular endothelial growth factor (VEGF), a drug suppressive of STAT3 (signal transducer and activator of transcription 3) signaling, an anticancer agent, a nanoparticle therapeutic agent loaded with such a drug, and a cell therapeutic agent for cancer.
- T helper 17 a drug suppressive of the immune response of Th17
- IL-6 interleukin 6
- VEGF vascular endothelial growth factor
- STAT3 signal transducer and activator of transcription 3
- the drug suppressive of the immune response of Th17 may be aspirin, and the drug suppressive of the formation or activity of VEGF may function to interrupt with VEGF receptor-mediated signaling.
- An anticancer agent-loaded nanoparticle may be a liposome such as DOXIL.
- microvesicles according to the claims may be present in a pharmaceutical composition which may comprise a pharmaceutically acceptable carrier, for example, saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, a dextrose solution, a maltodextrin solution, glycerol, ethanol, liposome, or a combination thereof.
- a pharmaceutically acceptable carrier for example, saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, a dextrose solution, a maltodextrin solution, glycerol, ethanol, liposome, or a combination thereof.
- the pharmaceutical composition may further comprise a typical additive such as an antioxidant, a buffer, etc.
- the pharmaceutical composition may be formulated into injections such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules or tablets, with the aid of a diluent, a dispersant, a surfactant, a binder and/or a lubricant.
- the pharmaceutical composition may be formulated into suitable dosage forms according to a method that is well known in the art or the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA . No particular limitations are imparted to the formulations of the pharmaceutical composition.
- the pharmaceutical composition may be formulated into injections or inhalable forms.
- the pharmaceutical composition may be administered orally or parenterally such as intravenously, subcutaneously, intraperitoneally, via inhalation, or topically.
- the amount of the active ingredient in the pharmaceutical composition may vary depending on various factors including a patient's weight, age, gender and health condition, diet, the time of administration, the route of administration, the rate of excretion, the severity of disease, and the like.
- the term "daily dose” means an amount of the therapeutically effective ingredient which is sufficient to reduce the condition of disease when it is administered to a subject in need thereof.
- a suitable dose of the active ingredient in the pharmaceutical composition may depend on the kind of the loaded compounds, disease severity, and the condition of a subject in need of treatment, and can be determined by those skilled in the art.
- the suitable dose of the composition may vary depending on a patient's weight, age, gender and health condition, the route of administration, and the severity of disease, and generally ranges from 0.1 to 1000 mg/day, and preferably from 1 to 500 mg/day, based on adult patients with a weight of 70kg.
- the total effective amount of the pharmaceutical composition can be administered to patients in a single dose or can be administered by a fractionated treatment protocol, in which multiple doses are administered over a more prolonged period of time.
- the term "subject” refers to an animal in need of the treatment of cancer, including a human, or non-human mammals such as primates, mice, rats, dogs, cats, horses, cows, etc.
- cancer refers to a group of different diseases, which are characterized by unregulated cell growth and infiltration to neighboring tissues due to the disruption of programmed cell death.
- a target to be treated according to the present invention may be selected from a cancer selected from the group consisting of, but not limited to, carcinoma originating from epithelial cells, such as lung cancer, larynx cancer, stomach cancer, large intestine/rectal cancer, liver cancer, gallbladder cancer, pancreatic cancer, breast cancer, uterine cervical cancer, prostate cancer, kidney cancer, skin cancer, etc., sarcoma originating from connective tissue cells, such as bone cancer, muscle cancer, fat cancer, fibrous cell cancers, etc., blood cancer originating from hematopoietic cells, such as leukemia, lymphoma, multiple myeloma, etc., and neuroma, a tumor of nervous tissues.
- the bacterial cell-derived microvesicles according to the claims may be loaded with a drug which functions to neutralize the side effects of the microvesicles themselves.
- the side effects can additionally be reduced by a drug functioning as an anti-inflammatory and/or anti-coagulant agent.
- the drug may include aspirin.
- aspirin When administered in combination with the bacterial cell-derived microvesicles, aspirin prevents the microvesicle-induced side effects such as inflammatory responses, blood coagulation, etc.
- microvesicles may be constructed from bacteria that have been cultured in the presence of the drug.
- the side effects may additionally be reduced by chemically modifying membrane components of the bacterial cell-derived microvesicles.
- the membrane components may be chemically modified with thiol or amine groups or by bonding polyethylene glycol to the membrane.
- Bacterial infection which may occur upon the administration of bacterial cell-derived microvesicles, may be prevented by sterilization.
- the bacterial cell-derived microvesicles are sterilized using UV or gamma radiation or through filtration to kill or remove bacteria.
- microvesicles according to the claims loaded with a drug that potentiates anticancer activity may be used.
- This drug may be as described above.
- the microvesicles according to the claims may be administered to a subject, in combination with a drug suppressive of side effects of microvesicles and/or a drug potentiating anticancer activity, a nanoparticle therapeutic agent loaded with such a drug, and a cell therapeutic agent.
- the nanoparticle therapeutic agent is a particle with a size of 10 nm ⁇ 10 ⁇ m, and examples thereof include, but are not limited to, liposomes, dendrimers, polymers, and microvesicles
- loading refers to, but not limited to, a process of displaying a substance of interest on the surface of the bacterial cell-derived microvesicles or of encapsulating the substance within the microvesicles.
- Also disclosed is a method for the preparation of shedding microvesicles for cancer therapy or diagnosis which comprises: adding a drug to a suspension of bacteria or transformed bacteria to give a bacterial suspension containing the drug; and isolating shedding microvesicles loaded with the drug from the bacterial suspension; or isolating shedding microvesicles from a culture of bacteria or transformed bacteria; and incubating a suspension of the isolated microvesicles with a drug.
- This method may further comprise isolating shedding microvesicles loaded with the drug for cancer therapy or diagnosis.
- the method for the preparation of shedding microvesicles for cancer therapy or diagnosis disclosed herein may further comprise sterilizing the shedding microvesicles using a process selected from the group consisting of antibiotic treatment, UV exposure, gamma ray exposure, and filtration.
- the preparation method disclosed herein may further comprise isolating sub-cell sized, drug-loaded microvesicles.
- This isolating step may be carried out using a process selected from the group consisting of a density gradient, ultracentrifugation, filtration, dialysis and free-flow electrophoresis.
- the preparation method may further comprise removing microvesicles whose membranes are topologically different from those of the bacterial cells of origin. After construction of microvesicles, only those microvesicles that have the same membrane topology as that of the source cells may be selected according to purposes. Using antibodies recognizing cytoplasmic domains of membrane proteins, microvesicles in which the cytoplasmic domains are exposed to the outside can be removed. That is, the microvesicles in which the plasma membrane is turned inside out are removed, and only the microvesicles in which the extracellular domains of membrane proteins are positioned so as to be directed towards the outside remain.
- the substance to be loaded to the bacterial cell-derived microvesicles may be one used for therapy and/or diagnosis, or a protein expressed by the bacteria or transformed bacteria themselves.
- the loading substance may not be native to the cells, but may be a foreign material. That is to say, the therapeutic and/or diagnostic substance may be at least one derived from the bacteria or introduced from the outside of the bacterial cells.
- the substance may be loaded to the surface of microvesicles using, but not limited to, physical, chemical and/or biological methods.
- the bacterial cell-derived microvesicles according to the claims may be loaded with the various therapeutic or diagnostic substances in various manners as follows.
- microvesicles can be prepared from cells which have already been loaded with a therapeutic or diagnostic substance of interest.
- a therapeutic or diagnostic substance of interest For example, when cells are cultured in a medium containing the therapeutic or diagnostic substance of interest, they may contain the substance therein. Alternatively, the substance may be introduced into cells by electroporation.
- microvesicles which shed from the cells containing the substance are loaded with the substance.
- shedding microvesicles may be loaded with a substance of interest after they are formed.
- the loading can be achieved by electroporating the substance into already prepared shedding microvesicles.
- therapeutic substances useful in the present invention are anticancer agents, anti-inflammatory agents, angiogenesis inhibitors, peptides, proteins, toxins, nucleic acids, beads, microparticles and nanoparticles, but the present invention is not limited thereto.
- nucleic acids examples include DNA, RNA, aptamers, LNA (locked nucleic acid), PNA (peptide nucleic acid), and morpholinos, but are not limited thereto.
- nanoparticles include iron oxide, gold, carbon nanotubes, and magnetic beads, but are not limited thereto.
- a diagnostic substance may be a fluorophore.
- the fluorophore may be a fluorescent protein or quantum dot (Qdot).
- the therapeutic substance may be one or more anticancer agents.
- the microvesicles for use according to the present invention may be guided to specific cells or tissues.
- the specific tissues may include, but are not limited to, blood vessels, cancer and inflammatory tissues.
- a substance therapeutic or diagnostic for a disease, a nanoparticle therapeutic agent loaded with a substance therapeutic and/or diagnostic agent, and a cell therapeutic agent can be delivered with the aid of the microvesicles disclosed herein.
- Two or more different therapeutic or diagnostic substances may be delivered to specific cells or tissues.
- Two or more different microvesicles selected from the group consisting of a microvesicle loaded with one therapeutic or diagnostic substance, a microvesicle loaded with two or more different therapeutic or diagnostic substances, and a combination thereof may be used to deliver the therapeutic or diagnostic substance(s).
- two or more different microvesicles may be administered simultaneously.
- kits for the diagnosis of a disease comprising bacterial cell-derived microvesicles loaded with a diagnostic substance.
- the diagnostic substance may be selected from the group consisting of a primer, a probe, an antisense nucleic acid, and an antibody.
- microvesicles according to the claims derived from cells targeting a specific tissue or from transformed cells expressing a targeting protein may be employed.
- the microvesicles according to the claims may be derived from transformed cells expressing a fusogen.
- the blood cells that is, monocytes, lymphocytes, neutrophils, eosinophils, basophils, and platelets, myeloid-derived suppressor cells, and stem cells found in bone marrow, blood, and adipose tissues are guided to cancerous and inflammatory tissues.
- Microvesicles derived from bacteria which are transformed to express a protein binding selectively to a substrate expressed on a specific cell or tissue can be guided to the specific cell or tissue.
- microvesicles constructed from such bacterial cells can be used to deliver the substances to target cells, tissues or blood.
- cell adhesion molecules including integrins such as LFA-1 (leukocyte function-associated antigen-1) and Mac-1 (macrophage-1 antigen) are present on the surface of monocytes.
- LFA-1 leukocyte function-associated antigen-1
- Mac-1 macrophage-1 antigen
- cell adhesion molecules can bind to other cell adhesion molecules, such as ICAM-1 (intercellular adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1), on vascular cells. Interaction between LFA-1 and ICAM-1 allows monocytes to pass through vascular endothelial cells so that the monocytes can be guided to inflammatory or cancerous tissues.
- microvesicles When transformed to express plasma membrane proteins specific for cancer or tissues of interest on the surface of bacterial cell-derived microvesicles, the microvesicles can be guided to specific tissues, such as vascular tissues, cancerous or tumorous tissues, etc.
- tissue such as vascular tissues, cancerous or tumorous tissues, etc.
- ERBB2 is overexpressed on the surface of breast cancer cells.
- Microvesicles derived from bacteria which have been transformed to express a fusion protein composed of a bacterial transmembrane protein and an antibody specific for the membrane protein ERBB2 can be allowed to target breast cancer tissues.
- bacterial cell-derived microvesicles can be guided toward large intestine cancer, pancreatic cancer and lung cancer tissue if they are transformed to express a fusion protein in which an antibody recognizing a carcinoembryonic antigen (CEA) abundantly found in the cancer tissues is fused to a bacterial transmembrane protein.
- CEA carcinoembryonic antigen
- Bacterial cell-derived microvesicles retain almost the same membrane components as those of the bacterial cells of origin, so that they can be directed toward specific tissues or cells that the bacteria target. If necessary, a nuclease may be employed during the construction of microvesicles to remove nucleic acids unnecessary for the delivery of a therapeutic or diagnostic substance from the microvesicles.
- microvesicles can be readily loaded with various therapeutic or diagnostic substances to be delivered.
- microvesicles may be used for mono- or combined therapy or diagnosis or both of therapy and diagnosis (theragnosis, pharmacodiagnosis).
- the substances to be delivered may be present inside the microvesicles when encapsulated, within the lipid bilayer when at least partially buried or embedded therein like a transmembrane protein, or on the surface of the microvesicles.
- microvesicles can be artificially constructed in various sizes like liposomes. Thanks to the EPR (Enhanced Permeability and Retention) effect, generally, molecules with a size of 100 nm or greater may accumulate in cancer tissue for a longer period of time than they do in normal tissues. Accordingly, a drug loaded to microvesicles with a size of 100 nm or greater is advantageous in diagnosis and therapy because it can stay much longer in cancer tissue, thereby enhancing a therapeutic or diagnostic effect. On the other hand, when inhaled, only particles with a size of 1 ⁇ m or smaller are allowed to reach the alveoli due to the pulmonary structure.
- EPR Enhanced Permeability and Retention
- a substance for example, an inflammation inhibitor for the treatment of asthma, can be delivered to lung tissue if it is loaded to microvesicles which are smaller than 1 ⁇ m in size.
- various sizes of microvesicles may be constructed depending on the tissue to which the loaded substance is to be applied.
- the microvesicles for use according to the present invention range in size from 10 nm to 10 ⁇ m.
- an immunosuppressant When a therapeutic substance loaded to the microvesicles according to the claims is administered to a "subject", an immunosuppressant may be used together therewith.
- Microvesicles according to the claims may be constructed from all kinds of bacterial cells, for example, bacteria that can be directed to a target, such as specific cells or tissues, by transformation. Microvesicles may be constructed from bacterial cells which are directed toward the specific tissue. Also, when constructed from cells in which proteins directed toward specific tissues are upregulated and/or proteins involved in non-specific guidance are downregulated, microvesicles can be effectively used to deliver a therapeutic or diagnostic substance to, for example, blood vessels, cancer tissues, or inflammatory tissues.
- the transformation of bacterial cells can be achieved using typical methods known in the art, for example, by stimulating the cells or introducing a foreign gene into the bacterial cells to modify, e.g., upregulate or downregulate, the expression of proteins of interest.
- a specific stimulus may induce a change in the expression of a protein of interest.
- the introduction of a foreign gene may induce the expression or inhibition of a protein of interest.
- plasmid DNA, RNA or a phage is introduced into cells using electroporation, microinjection, ultrasound mediation or other methods known in the art.
- microvesicles can be constructed from the bacterial cells.
- microvesicles may be prepared from bacterial cells expressing a therapeutic and/or diagnostic substance or bacterial cells transformed to express a therapeutic and/or diagnostic substance.
- microvesicles may be prepared from bacterial cells expressing a combination of the above substances or bacterial cells transformed to express a combination of the above substances.
- antisense RNA, LNA, PNA, and the like can be used.
- the bacterial cells When microvesicles constructed from bacterial cells are directed toward two targets, the bacterial cells may be transformed in such a way that the expression of one or more specific proteins is inhibited to reduce the guidance of the cells to one of the two targets. Hence, the specificity in the delivery of the substance for microvesicles derived from the transformed cells is enhanced.
- bacterial cells which have undergone two or more rounds of transformation may be used. For example, primary transformants may be subjected to secondary transformation before being used as a source for constructing microvesicles.
- the substance useful in the present invention may include, but is not limited to, a substance that bacteria or transformed bacteria express or a foreign substance that the bacteria do not express.
- a therapeutic substance may be loaded to microvesicles according to the claims or may be administered in combination with microvesicles according to the claims according to needs and purposes.
- the therapeutic substance may be administered as it is or as a complex with a nanoparticle therapeutic agent or cell therapeutic agent, in combination with microvesicles according to the claims.
- various materials including proteins or peptides, nucleic acids, lipids and metabolites, all being derived from nucleated, mammalian cells, may be used without limitation.
- loadable proteins or peptides useful in the present invention include, but are not limited to, growth factors, such as VEGF, EGF (epidermal growth factor), etc., cytokines such as IL-1, IFN- ⁇ (interferon-gamma), IL-10, etc., antibodies, receptors, and fluorescent proteins.
- the proteins or peptides may be expressed within cells or displayed on plasma membranes. Also, their entirety or active sites may be expressed solely or as fusion proteins. It is known that the activity of proteins or peptides displayed on microvesicles is higher than when they exist solely within cells as a result of the higher local concentration. Proteins or peptides on microvesicles may act as ligands to trigger signaling or as antagonists to inhibit the function of various ligands.
- nucleic acids loadable to the microvesicles or the nanoparticle or cell therapeutic agent according to the present invention include DNA, miRNA (microRNA), siRNA (small inferring RNA), antisense RNA, and sense RNA, but are not limited thereto. These nucleic acids may be used to evoke sense effects, antisense effects, RNA interference, or inhibition of protein functions.
- anticancer agents As the foreign therapeutic or diagnostic substance loadable to the microvesicles or the nanoparticle or cell therapeutic agent, anticancer agents, anti-inflammatory agents, angiogenesis inhibitors, peptides, proteins, toxins, nucleic acids, beads, microparticles and nanoparticles may be used without limitation.
- An anticancer agent is a generic term of a drug used to suppress the growth and metastasis of cancer. Most anticancer agents act to block the replication, transcription and/or translation of cancer cells. No particular limitations are imparted on the kinds of anticancer agents useful in the present invention. Under the general principle in which the kinds of cancer cells, absorption rates of anticancer agents (the duration of treatment, the route of administration, etc.), positions of tumor, sizes of tumor, etc. are taken into consideration, anticancer agents may be selected.
- anticancer agents useful in the present invention include DNA alkylating agents, such as mechlorethamine, chlorambucil, phenylalanine, mustard, cyclophosphamide, ifosfamide, carmustine (BCNU), lomustine (CCNU), streptozotocin, busulfan, thiotepa, cisplatin and carboplatin, anti-cancer antibiotics, such as dactinomycin (actinomycin D), doxorubicin (adriamycin), epirubicin, idarubicin, mitoxantrone, plicamycin, mitomycin and C Bleomycin, and plant alkaloids, such as vincristine, vinblastine, paclitaxel, docetaxel, daunorubicin, taxol, oncovin, prednisone, cisplatin, herceptin, rituximab, etoposide, teniposide, topote
- the anti-inflammatory agent loadable to the microvesicles according to the claims or the nanoparticle or cell therapeutic agent is selected from the group consisting of, but not limited to, dexamethasone, indomethacin, ibuprofen, clobetasol propionate, diflorasone diacetate, halobetasol propionate, amcinonide, fluocinonide, mometasone furoate, desoximetasone, diclofenac and piroxicam.
- angiogenesis inhibitor refers to a drug that functions to suppress the growth of new blood vessels from preexisting vessels. Most angiogenesis inhibitors have the function of suppressing the growth and metastasis of cancer, and inflammatory reactions. No particular limitations are imparted to the kinds of the angiogenesis inhibitors available as the therapeutic substance useful in the present invention.
- the therapeutic substance loaded to the microvesicles according to the claims or the nanoparticle or cell therapeutic agent may include proteins or peptides.
- proteins or peptides For example, RNase A, growth factors, such as VEGF and EGF, cytokines, such as IL-1, IFN-gamma and IL-10, antibody therapeutics, DNase, and various proteins or peptides suppressing the growth and metastasis of cancer cells and inflammatory responses may be employed without limitations.
- the therapeutic substance loaded to the microvesicles according to the claims or the nanoparticle or cell therapeutic agent may include toxins.
- toxins refers to a poisonous substance produced within living cells or organisms, which is capable of causing a disease on contact with or adsorption by body tissues. Using a toxin, cell death can be induced. No particular limitations are imparted to the kind of toxin available as the therapeutic substance useful in the present invention.
- nucleic acids loadable to the microvesicles according to the claims or the nanoparticle or cell therapeutic agent are DNA, miRNA, siRNA, antisense RNA, sense RNA, and aptamers.
- nucleic acid analogs such as LNA, PNA, and morpholinos may be loaded to the microvesicles or the nanoparticle or cell therapeutic agent, but not limited thereto. These nucleic acids may be used to evoke sense effects, antisense effects, RNA interference, or inhibition of protein functions.
- microvesicles loaded with nucleic acids encoding fluorescent proteins or with various fluorescents can be used for diagnosis.
- microvesicles designed to target specific cells or tissues are loaded with a plasmid DNA carrying a gene encoding a fluorescent protein and introduced into the body, the fluorescence signal emitted from the fluorescent protein makes it possible to recognize where the target cells or tissues exist.
- fluorescent quantum dots or other various fluorescents may be loaded to microvesicles and used to detect the position of specific cells and tissues within the body. That is, fluorescence generated from target cells or tissues can be used for diagnosis.
- fluorescence-emitting quantum dots may be applied to the treatment of diseases because they induce apoptosis.
- Therapeutic or diagnostic substances other than fluorescents, loadable to the microvesicles may be exemplified by microparticles or nanoparticles.
- examples include iron oxide particles, gold particles and carbon nanotubes, but are not limited thereto.
- Magnetic beads may be used as the therapeutic or diagnostic substance and loaded into the microvesicles.
- Magnetic particles such as iron oxide may be used as an image contrasting agent for MRI (magnetic resonance imaging).
- nucleic acids or proteins conjugated with nanoparticles may be employed. Diagnostic radioactive substances are also available.
- Two or more different substances can be delivered by the microvesicles according to the claims.
- the microvesicles according to the claims with two or more different substances simultaneously loaded thereto may be used to deliver the substances.
- microvesicles according to the claims loaded with different substances individually or in combination are employed in combination so that two or more different substances can be delivered.
- a first, a second and a third microvesicle according to the claims may be loaded with the three different substances, respectively.
- a fourth microvesicle according to the claims with two different substances simultaneously loaded thereto and a fifth microvesicle according to the claims with another different substance loaded thereto may be used to deliver the three different substances.
- the first, the second and the third microvesicles according to the claims may be used simultaneously or sequentially.
- the fourth and the fifth microvesicles according to the claims may be used simultaneously or sequentially.
- a density gradient process one of the most popular processes for distinguishing materials with different densities, can be applied to the isolation of the microvesicles according to the claims because their densities are different from those of free molecules.
- a medium may be selected from among, but not limited to, Ficoll, glycerol, sucrose and OptiPrepTM.
- Microvesicles loaded with or without therapeutic or diagnostic substances may be separated from each other when taking advantage of differences in density therebetween.
- a density gradient process may be used in combination with centrifugation or electrophoresis.
- Microvesicles can also be isolated by gel filtration or ultrafiltration. Instead of filtration, dialysis may be adopted to remove small molecules. In addition, free flow electrophoresis is useful for isolating microvesicles.
- microvesicles within a certain size range may be selected before use.
- the selection of microvesicles within a certain size range may be carried out before, simultaneously or after loading therapeutic or diagnostic substances thereinto.
- Microvesicles in which a part of membrane components have been modified may be constructed. For example, when microvesicles are constructed from a mixture of a fusion protein and cells, the fusion protein may be at least partially exposed on the microvesicles. Microvesicles may be converted into stealth-microvesicles by coating with polyethylene glycol. The addition of cyclodextrin to microvesicles may reduce the non-specific targeting of the microvesicles. Exhibiting both hydrophilicity and hydrophobicity, cyclodextrin, when attached onto the surface of microvesicles, can act to block non-specific binding between lipids. The microvesicles or shedding microvesicles may be chemically modified.
- microvesicles are constructed from cells whose membrane or transmembrane proteins are at least in part exposed to the outside, various molecules may be chemically bound to the thiol group of cysteine residues on the exposed region of the protein.
- membrane components of the microvesicles can be modified by chemical biding of various molecules to the amine group within a membrane protein.
- the bacteria useful in the present invention may be Gram-negative or Gram-positive.
- Exemplary among the Gram-negative bacteria are E. coli , Pseudonomas aeruginosa , and Salmonella sp.
- Examples of the Gram positive bacteria include Staphylococcus aureus and Lactobacillus aciophilus , but are not limited thereto.
- microvesicles examples include proteins, nucleic acids, and lipids, but are not limited thereto.
- the proteins present as one of the components of the bacterial cell-derived microvesicles according to the claims, include water-soluble proteins, lipid-soluble proteins, or membrane proteins, but are not limited thereto.
- the microvesicles as defined in the claims may comprise membrane proteins including OmpA, OmpF, OmpC, and flagellin, but not limited thereto.
- the microvesicles as defined in the claims may comprise nucleic acids including DNA and RNA, but not limited thereto.
- the microvesicles as defined in the claims may comprise proteins associated with at least one selected from the group consisting of, but not limited to, a cell adhesion molecule, an antibody, a targeting protein, a cell membrane fusion protein, and a fusion protein thereof
- EXAMPLE 1 (comparative Example)Construction of Artificial Microvesicles Derived from Gram-Negative Bacteria by Extrusion and Properties Thereof
- E. coli was employed. E. coli was cultured to an optical density of 1.0 (at 600 nm) in 50 mL of LB broth. The bacteria cells were collected as a pellet after centrifugation at 3,500 x g for 10 min, and the cell pellet was resuspended in PBS (phosphate buffered saline).
- PBS phosphate buffered saline
- This cell suspension was passed three times through each of membrane filters with a pore size of 10 ⁇ m, 5 ⁇ m, and 1 ⁇ m, in that order.
- 1 mL of 50 % OptiPrep, 1 mL of 5 % OptiPrep, and 3 mL of the cell suspension effluent from the membrane filters were sequentially placed.
- Ultracentrifugation at 100,000 ⁇ g for 3 hrs formed a layer of microvesicles between 50 % OptiPrep and 5 % OptiPrep.
- the artificial microvesicles constructed from the Gram-negative bacterium were analyzed for properties.
- the Gram-negative bacterial cell-derived, artificial microvesicles were adsorbed for 3 min to a glow-discharged carbon-coated copper grid.
- the grid was washed with distilled water, and stained for 1 min with 2 % uranylacetate before observation under a JEM101 electron microscope (Jeol, Japan).
- the result is shown in FIG. 1 .
- the microvesicles artificially constructed from bacterial cells by extrusion consisted of a lipid bilayer, and were generally spherical with a size of 10 ⁇ 100 nm.
- microvesicles that were spontaneously shed from Gram-negative bacteria were isolated.
- the Gram-negative bacteria E. coli , Pseudonomas aeruginosa , and Salmonella enteritidis were used as sources of microvesicles.
- Bacteria were inoculated into 100 mL of LB in an Erlenmeyer flask and cultured at 37°C for 6 hrs. Of the culture, 8 mL was transferred into 600 mL of LB broth in a 2 L Erlenmeyer flask and cultured at 37°C for 5 hrs to an optical density of 1.5 (at 600 nm).
- the resulting culture was divided into 500 mL high speed centrifuge tubes before centrifugation at 10,000 x g and 4°C for 20 min.
- the supernatant was forced to pass once through a membrane filter with a pore size of 0.45 ⁇ m, and then concentrated 25-fold using a Quixstand system equipped with a membrane having a molecular weight cut-off of 100 kDa.
- the concentrate was passed once through a membrane filter with a pore size of 0.22 ⁇ m, and divided into 70 mL ultracentrifuge tubes, followed by ultracentrifugation at 150,000 x g and 4°C for 3 hrs to afford bacteria cell-derived shedding microvesicles as a precipitate. This was suspended in PBS.
- the shedding microvesicles derived from E. coli , P. aeruginosa , and S. enteritidis were assayed for anticancer activity.
- a mouse colon 26 cell line was subcutaneously injected at a dose of 1 ⁇ 10 6 cells into mice, and cultured. After one week, a PBS solution containing 1 ⁇ g, or 5 ⁇ g of each of the Gram-negative bacterial cell-derived microvesicles was injected at a dose of 100 ⁇ l twice a week via the tail vein into the mice which were divided into groups, each consisting of three.
- the sizes of colon cancer tissue were monitored.
- FIGS. 2 to 4 After the subcutaneous transplantation, the volume measurements of colon cancer tissues were as shown in FIGS. 2 to 4 .
- the administration of shedding microvesicles derived from E. coli reduced the size of the colon cancer tissue in a dose-dependent manner, compared to the control PBS ( FIG. 2 ).
- a significant reduction in the size of colon cancer tissues was obtained after shedding microvesicles derived from P. aeruginosa were administered ( FIG. 3 ).
- the size of colon cancer tissue was reduced by shedding microvesicles derived from S. enteritidis ( FIG. 4 ).
- microvesicles that were spontaneously shed from Gram-positive bacteria were isolated.
- the Gram-positive bacteria Staphylococcus aureus and Lactobacillus acidophilus were used as sources of microvesicles.
- Bacteria were inoculated into 100 mL of a nutrient broth in an Erlenmeyer flask and cultured at 37°C for 6 hrs. Of the culture, 8 mL was transferred into 600 mL of a nutrient broth in a 2 L Erlenmeyer flask and cultured at 37°C for 5 hrs to an optical density of 1.5 (at 600 nm).
- the resulting culture was divided into 500 mL high speed centrifuge tubes before centrifugation at 10,000 x g and 4°C for 20 min.
- the supernatant was forced to pass once through a membrane filter with a pore size of 0.45 ⁇ m, and then concentrated 25-fold using a Quixstand system equipped with a membrane having a molecular weight cut-off of 100 kDa.
- the concentrate was passed once through a membrane filter with a pore size of 0.22 ⁇ m, and divided into 70 mL ultracentrifuge tubes, followed by ultracentrifugation at 150,000 x g and 4°C for 3 hrs to afford bacteria cell-derived shedding microvesicles as a precipitate. This was suspended in PBS.
- the shedding microvesicles derived from S. aureus and Lactobacillus acidophilus were assayed for anticancer activity.
- a mouse colon 26 cell line was subcutaneously injected at a dose of 1 ⁇ 10 6 cells into mice, and cultured. After one week, a PBS solution containing 10 ⁇ g of each of the Gram-positive bacterial cell-derived microvesicles was injected at a dose of 100 ⁇ l twice a week via the tail vein into the mice which were divided into groups, each consisting of three.
- the sizes of colon cancer tissue were monitored.
- FIGS. 5 and 6 After the subcutaneous transplantation, the volume measurements of colon cancer tissues were as shown in FIGS. 5 and 6 . As can be seen in the graphs, a significant reduction in the size of colon cancer tissues was obtained after shedding microvesicles derived from S. aureus ( FIG. 5 ) or L. acidophilus ( FIG. 6 ) were administered, compared to the control PBS.
- the volume measurements of colon cancer tissues were as shown in FIG. 7 .
- the mouse group when administered with the shedding microvesicles derived from the mutant E . coli which had been transformed to have reduced LPS toxicity, was observed to have a significantly decrease in tumor size, compared to the control administered with PBS only. Also, the colon cancer of the mutant group was much smaller in size than that of the wild-type group.
- the volume measurements of colon cancer tissues were as shown in FIG. 8 .
- the mouse group when administered with the shedding microvesicles derived from the mutant S . aureus which had been transformed to have reduced toxicity of lipoteichoic acid, was observed to significantly decrease in tumor size, compared to the control administered with PBS only. Also, the colon cancer of the mutant group was much smaller in size than that of the wild-type group.
- the mouse melanoma cell line (B16BL6) was injected at a dose of 1 ⁇ 10 5 cells into mice via the tail vein and cultured. After three days, PBS, or PBS containing 1 ⁇ g of the shedding microvesicles derived from E. coli that had been transformed to have reduced LPS toxicity, was injected at a dose of 100 ⁇ l in a day for 10 days via the tail vein into mouse groups, each consisting of three mice. On day 14 after the injection of the melanoma cells, the lungs were excised from the mice to count melanoma colonies metastasized to the lung.
- FIG. 9 is a graph showing numbers of melanoma colonies metastasized to the lung in each mouse group of three. As can be seen in FIG. 9 , the mice administered with the microvesicles derived from E. coli that had been transformed to have reduced LPS toxicity were found to have much fewer melanoma colonies metastasized to the lung, compared to the PBS control.
- EXAMPLE 7 Anticancer Activity upon Co-Administration of Bacterial Cell-Derived Shedding Microvesicles and Drug
- FIG. 10 After the subcutaneous transplantation, the volume measurements of colon cancer tissues were as shown in FIG. 10 . As can be seen in FIG. 10 , there was no differences in the size of colon tumors between the group administered with aspirin alone and the control group administered with PBS alone. That is, the anticancer effect of aspirin was not observed. However, the size of colon tumors was significantly further reduced when the shedding microvesicles derived from E. coli that had been transformed to have reduced LPS toxicity were administered in combination with aspirin than alone.
- the data obtained above demonstrate that when co-administered together with a drug suppressive of the immune response of Th17, such as aspirin, the bacterial cell-derived shedding microvesicles suitable for use according to the present invention exerts greater anticancer activity.
- EXAMPLE 8 Loading of Anticancer Drug to Gram-Negative Bacterial Cell-Derived Shedding Microvesicles
- the shedding microvesicles were mixed at a ratio of 1:1 with 0.4 mg/ml of doxorubicin and incubated at 4°C for 12 hrs. Thereafter, the suspension was ultracentrifuged at 150,000 ⁇ g and 4°C for 3 hrs to separate shedding microvesicles from doxorubicin-loaded microvesicles.
- the doxorubicin-loaded microvesicles were incubated with DiO, a liphophilic trace with green fluorescence that can bind to cell membranes. DiO-labeled microvesicles were instilled on a cover glass, followed by observation under a confocal microscope to examine whether doxorubicin was loaded to the shedding microvesicles. The fluorescence images are given in FIG. 11 .
- Anticancer agent-loaded, bacterial cell-derived microvesicles were assayed for anticancer activity to examine whether the anticancer agent load has an influence on the activity of the microvesicles themselves.
- Doxorubicin was used as an anticancer agent.
- a mouse colon 26 cell line was seeded at a density of 5 ⁇ 10 4 cells into 24-well plates and cultured overnight.
- the cancer cells in each well were treated for 6 hrs with 1 mL of PBS or a PBS solution containing the bacterial cell-derived microvesicles loaded with or without doxorubicin, and then incubated for 18 hrs.
- Viable mouse colon cancer 26 cells were counted under a microscope, and the results are given in FIG. 12 .
- doxorubicin-loaded, bacterial cell-derived microvesicles exerted greater inhibitory activity against cancer cells than did bacterial cell-derived microvesicles void of doxorubicin.
- Lipopolysaccharide a component of bacterial cell-derived microvesicles, is known to play an important role one the onset of sepsis.
- an inhibitor of lipopolysaccharides that the microvesicles retain was examined for effects on the side effects of the microvesicles.
- polymyxin B was employed as an LPS inhibitor.
- E . coli -derived shedding microvesicles were constructed according to the method described in Example 2.
- PBS, a PBS solution 25 ⁇ g of E . coli-derived shedding microvesicles, a PBS solution containing 25 ⁇ g of E . coli -derived shedding microvesicles plus 250 ⁇ g of polymyxin B were intraperitoneally injected at a dose of 100 ⁇ l into respective mouse groups, after which the survival rates of the mice were monitored at regular intervals of 12 hrs for 120 hrs. The results are given in FIG. 13 .
- the survival rate of the mice was 10 % at 120 hrs after administration with a PBS solution containing 25 ⁇ g of E . c oli -derived shedding microvesicles, but increased to 55 % in the same period of time after administration with a PBS solution containing 25 ⁇ g of E . coli -derived shedding microvesicles plus 250 ⁇ g of polymyxin B.
- Shedding microvesicles were constructed in the same manner as in Example 2 from E. coli transformed to have reduced toxicity of lipopolysaccharides.
- PBS, a PBS solution 25 ⁇ g of shedding microvesicles derived from wild-type E . coli, and a PBS solution containing 25 ⁇ g of shedding microvesicles derived from the mutant E. coli were intraperitoneally injected at a dose of 100 ⁇ l into respective mouse groups, after which the survival rates of the mice were monitored at regular intervals of 12 hrs for 120 hrs. The results are given in FIG. 14 .
- the survival rate of the mice was 45 % at 120 hrs after administration with a PBS solution containing 25 ⁇ g of the wild-type E. coli -derived shedding microvesicles, but increased to 65 % at the same period of time after administration with a PBS solution containing 25 ⁇ g of the mutant E. coli -derived shedding microvesicles.
- shedding microvesicles were isolated in the same manner as in Example 2, from the E. coli transformed to have reduced toxicity of lipopolysaccharides.
- Mouse colon 26 cell line was subcutaneously injected at a dose of 1 x 10 6 cells into mice, and cultured. After one week, PBS or a PBS solution containing 5 ⁇ g of shedding microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides was injected via the tail vein into mouse groups, each consisting of two mice. After 3 or 6 hrs after, blood samples were taken from the mice.
- the blood samples were 100-fold diluted in a dilution fluid (Rees-Ecker fluid), and incubated for 10 min at room temperature in a hemocytometer before counting platelets under an optical microscope. The results are given in FIG. 15 .
- D-dimer is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis, and thus serves as a diagnostic criterion for disseminated intravascular coagulation.
- the blood samples taken from Example 12 were centrifuged 1,300 x g for 10 min.
- the blood plasma thus obtained was 3-fold diluted and plated into 96-well plates coated with a capture antibody recognizing D-dimer.
- a hydrogen peroxidase-conjugated detection antibody specific for D-dimer was added. Afterwards, a color was developed with the substrate BM-POD, and the results are given in FIG. 16 .
- the shedding microvesicles derived from the E. coli that had been transformed to have reduced toxicity of lipopolysaccharides cannot destroy erythrocytes.
- the shedding microvesicles derived from E. coli that that had been transformed to have reduced toxicity of lipopolysaccharides do not cause, even when injected intravenously, a decrease in the number of platelets, blood coagulation, and hemolysis. Therefore, the side effects of bacterial cell-derived microvesicles can be effectively reduced when the bacteria have been transformed to have reduced toxicity of lipopolysaccharides.
- Lipoteichoic acid is known to induce inflammation through specific immune responses, and thus contributes to the side effects of Gram-positive bacterial cell-derived microvesicles because it is a component of the cell wall of Gram-positive bacteria.
- microvesicles derived from bacteria that had been transformed to lack a gene involved in the biosynthesis of lipoteichoic acid were used to evaluate the role of lipoteichoic acid in the side effects of Gram-positive bacterial cell-derived microvesicles.
- the LTA mutant was employed as the S. aureus transformed to remove lipoteichoic acid from the cell wall.
- Shedding microvesicles were constructed in the same manner as in Example 3 from S. aureus transformed to have reduced toxicity of lipoteichoic acid. After being isolated from the abdominal cavity of mice, macrophages (2.5 x 10 5 cells) were incubated for 12 hrs with 0.5 mL of each of PBS, a PBS containing 0.1 ⁇ g/ml of wild-type S . aureus-derived shedding microvesicles, and a PBS solution containing 0.1 ⁇ g/ml of the mutant S. aureus -derived shedding microvesicles, and the conditioned media were centrifuged at 500 x g for 5 min.
- Each well of 96-well plates coated with an IL-6 capture antibody was blocked for 1 hr with 100 ⁇ l of 1 % BSA (bovine serum albumin).
- the conditioned media was diluted by half, added to the plates, and incubated at room temperature for 2 hours and then for an additional 2 hrs in the presence of a biotinylated detection antibody against IL-6.
- the plates were washed with 1 % BSA, and incubated for 30 min with streptavidin-POD, followed by developing a color with the substrate BM-POD. The results are given in FIG. 18 .
- the level of IL-6 was reduced when shedding microvesicles derived from S. aureus that had been transformed to have reduced toxicity of lipoteichoic acid were administered, compared to wild-type S. aureus-derived shedding microvesicles.
- microvesicle-triggered immune response that induces the release of inflammatory mediators, causing topical or systemic inflammatory responses, and a microvesicle-caused coagulation that leads to thromboembolism or disseminated intravascular coagulation.
- aspirin was employed as an anti-inflammatory and anti-coagulant drug with the aim of reducing the side effects of bacterial cell-derived microvesicles.
- a mouse colon 26 cell line was subcutaneously injected at a dose of 1 x 10 6 cells into mice, and cultured. Shedding microvesicles were isolated in the same manner as in Example 2 from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides. After one week, PBS, a PBS solution containing 18 mg/kg of aspirin, a PBS solution containing 0.1 ⁇ g of the bacterial cell-derived microvesicles, and a PBS solution containing 0.1 ⁇ g of the bacterial cell-derived microvesicles plus 18 mg/kg of aspirin were injected at a dose of 100 ⁇ l via the tail vein into respective groups of four twice a week.
- 0.2 ml of a blood sample was taken from the eye of each mouse, and placed in an anticoagulant tube containing 50 mM EDTA (ethylenediaminetetraacetic acid).
- 10 ⁇ l was mixed with 90 ⁇ l of 1 % HCl, and stored at room temperature for 7 min.
- White blood cells, indicative of systemic inflammation, in 10 ⁇ l of the mixture were counted using a hematocytometer. The result is given in FIG. 19 .
- EXAMPLE 15 Drug Delivery of Bacterial Cell-Derived Microvesicles to Cancer Tissue
- a mouse colon 26 cell line was subcutaneously injected at a dose of 1 x 10 6 cells into mice, and cultured for one week.
- PBS or a PBS solution containing 5 ⁇ g of shedding microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides was intravenously injected at a dose of 100 ⁇ l.
- 100 nm-sized green fluorescent beads were also intravenously injected, and allowed to sufficiently circulate through the body for 5 min. Thereafter, all the blood of the mice was substituted by PBS to remove fluorescent beads from blood vessels.
- Colon cancer tissues were excised, and cryosectioned at a thickness of 20 ⁇ m, followed by staining nuclei with 10 ⁇ g/ml of Hoechst dye. Fluorescent beads present within cancer tissues were observed under a confocal microscope. The results are given in FIG. 20 .
- the administration of bacterial cell-derived microvesicles leads to more effective delivery of a subsequently injected anticancer drug or anticancer drug-loaded carrier in a size of tens to hundreds nanometers to a cancer tissue.
- OmpA one of the most abundant outer membrane proteins of Gram-negative bacteria, was most abundantly found in shedding microvesicles.
- OmpA was assayed for anticancer activity.
- EXAMPLE 17 Anticancer Activity of Shedding Microvesicles Derived from Outer membrane Protein OmpF-Devoid Bacteria
- OmpF the outer membrane protein OmpF was also found to be a major component of bacterial cell-derived shedding microvesicles according to the proteomic analysis result of the present inventors. Thus, OmpF-induced anticancer activity of bacterial cell-derived shedding microvesicles was assayed.
- shedding microvesicles were obtained in the same manner as in Example 2, with the exception that OmpF-devoid E. coli was employed.
- a mouse colon 26 cell line was subcutaneously injected at a dose of 1 x 10 6 cells into mice, and cultured. After one week, PBS, a PBS solution containing 1 ⁇ g of wild-type E. coli -derived shedding microvesicles, and a PBS solution containing 1 ⁇ g of shedding microvesicles derived from OmpF-devoide E. coli were injected at a dose of 100 ⁇ l twice a week via the tail vein into respective mouse groups. On day 21 after the transplantation of cancer cells, the sizes of colon cancer tissue were monitored.
- V volume of cancer tissue
- the anticancer activity of the shedding microvesicles derived from OmpF-devoid E. coli was lower than that of the shedding microvesicles derived from wild-type E. coli.
- N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3 phosphoethanolamine sodium salt MPEG-DSPE
- HSPC fully hydrogenated soy phosphatidylcholine
- cholesterol was separately dissolved in a concentration of 3.19 mg/mL, 9.58 mg/mL, and 3.19 mg/mL, respectively, in chloroform, and the three lipid solutions were mixed at a ratio of 1:1:1. Then, chloroform was removed using nitrogen gas to form a thin film.
- Urea buffer (344 mM urea, 10 mM KCl, 10 mM HEPES (pH 7.0, 3 mM NaN 3 ) was added to this thin film, followed by ultrasonication at 56°C for 1 hr in a water bath sonicator.
- the resulting suspension was forced to pass five times through a membrane filter with a pore size of 1 ⁇ m, then five times through a membrane filter with a pore size of 400 nm, and finally five times through a membrane filter with a pore size of 100 nm to afford liposomes.
- urea buffer containing 280 ⁇ g of OmpA, followed by octyl- ⁇ -D-glucopyranoside to the final concentration of 1.1 %. After incubation at 37°C for 2 hrs, 15 ml of urea buffer was added. The resulting solution was ultracentrifuged at 100,000 x g for 1 hr. The pellet was suspended in 0.2 ml of urea buffer, and added to 50 % OptiPrep solution to form a final concentration of 30 %.
- OmpA was found to be loaded to liposomes.
- the OmpA protein when isolated, is in a denatured form because it exists together with a detergent.
- OmpA when reconstituted into liposomes, OmpA is found to exist as both folded and denatured forms. From the result, it is understood that OmpA can be reconstituted into liposomes.
- the bacterial cell-derived microvesicles for use according to the present invention can specifically deliver substances therapeutic for cancer to cells or tissues of interest, thereby increasing therapeutic efficacy.
- the bacterial cell-derived microvesicles with therapeutic and/or diagnostic substances loaded thereto and the preparation method thereof in accordance with the present disclosure may be used for in vitro and/or in vivo treatment, diagnosis or experiments.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
- The present invention relates to certain bacterial cell-derived spontaneously shedding microvesicles for use in the treatment of cancer.
- In 1813, Vautier reported the apparent cure of cancer in patients who concurrently suffered from gas gangrene caused by the infection of the anaerobic bacterium Clostridium perfringens. Since then, extensive studies have been undertaken on the deliberate injection of various bacteria including Salmonella typhimurium in addition to Clostridium, with the concept of bacteria-mediated cancer therapy. As a cancer grows over a certain size (approximately 1 mm3), it undergoes an undersupply of oxygen from surrounding vessels, with the formation of hypoxia within the cancer tissue. The cancer tissue in a hypoxia state provides an environment in which anaerobic bacteria are readily likely to proliferate while they might attack surrounding cancer cells to necrosis using various toxins and/or through unknown mechanisms. Various attempts have been made to enhance bacteria-mediated cancer therapy. For example, bacteria are transformed to express anticancer proteins, or are used to deliver a plasmid carrying an anticancer protein gene to a cancer tissue. To mitigate the side effects arising from bacterial proliferation and toxins, auxotrophic mutants, spores, and attenuated bacteria have also been tried for cancer therapy. In spite of these efforts, the use of bacteria in cancer therapy always has the risk of bacterial proliferation in normal tissues or organs surrounding the cancer mass.
- There are broadly speaking two different types of cell wall in bacteria, called Gram-positive and Gram-negative. Gram-negative bacteria, such as Escherichia coli, Neisseria meningitidis, Pseudomonas aeruginosa, and Shigella flexneri, are known to spontaneously shed microvesicles from the outer membrane. The Gram-negative bacterial cell-derived shedding microvesicles are known as outer membrane vesicles typically consisting of a lipid bilayer. They are generally spherical with a size of 20 ∼ 200 nm, and have various biologically active substances, such as lipopolysaccharide (LPS), and outer membrane proteins, lipids and genetic materials (DNA, RNA) which influence the inflammatory responses of host cells. Bacterial cell-derived shedding microvesicles serve as an information carrier which plays a role in the transport of proteins or genetic materials between homogeneous cells and in cell-to-cell signaling, and contributes to the removal of competitive organisms or the survival of bacteria. In addition, the shedding microvesicles deliver toxins to hosts, thus accounting, in part, for the etiology of bacterial diseases. Reports that shedding microvesicles were found in the blood of patients who died of severe sepsis suggest that shedding microvesicles play an important role in the pathology of sepsis, which is characterized by systemic inflammation. This is also supported by the research finding that bacterial cell-derived shedding microvesicles stimulate host cells to secrete inflammatory cytokines and coagulants.
- Gram-positive bacteria including Bacillus subtilis and Staphylococcus aureus produce shedding microvesicles, which was first found by the present inventors. However, there is a need for more information on components or functions of Gram-positive bacterial cell-derived shedding microvesicles.
- Microvesicles that spontaneously shed from various bacteria species have been isolated and observed. Typically, shedding microvesicles are isolated from cell cultures by filtration or ultracentrifugation. In addition, it is known that the production of shedding microvesicles can be controlled with an antibiotic such as gentamicin. Particularly, there is a suggestion that shedding microvesicles prepared by treatment with a detergent might be applied as a vaccine against the infection of N. meningitidis, a bacterial pathogen. However, the capacity of these production methods is seriously limited.
-
WO 87/07503 -
WO 91/12813 -
EP 2 027 865 discloses a liposome having a lipid membrane containing a bacterial cell component.
GABRI ET AL, CLINICAL CANCER RESEARCH, vol. 12, no. 23,(2006), pages 7092-7098 discloses antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model. -
US 2004/013689 discloses vaccines and pharmaceutical compositions using membrane vesicles of microorganisms. KYONG-SU PARK ET AL., PLOS ONE, vol. 5, no. 6, (2010) page e11334 discloses that outer membrane vesicles derived from Escherichia coli induce systemic inflammatory response syndrome. - In spite of the relationship between cancer and bacteria, there have been no reports on the role of bacterial cell-derived shedding microvesicles in the onset and progression of cancer, particularly, on the application of bacterial cell-derived shedding microvesicles to the treatment and/or diagnosis of cancer, thus far.
- Leading to the present invention, intensive and thorough research of the present inventors resulted in the finding that a composition comprising microvesicles derived from bacteria or transformed bacteria can effectively suppress the growth of cancer.
- The present invention provides bacterial cell-derived spontaneously shedding microvesicles for use in the treatment of cancer, wherein
- (a) the microvesicles are administered simultaneously or sequentially with a drug that is suppressive of the toxicity of endotoxin of the microvesicles;
- (b) the microvesicles are loaded with a drug that is suppressive of the toxicity of endotoxin of the microvesicles; and/or
- (c) the bacteria are transformed to have a modified gene involved in formation of an endotoxin so that the microvesicles are mitigated in toxicity.
- The bacteria used in the present invention may come from Gram-positive or Gram-negative bacteria, and may be native or genetically transformed.
- A nanoparticle therapeutic agent may be loaded with such a drug and/or cell therapeutic agent.
- The microvesicles according to claim 1 may be administered simultaneously/sequentially together with a drug that neutralizes the toxicity of endotoxin of the microvesicles, a drug that enhances anticancer activity, a nanoparticle therapeutic agent loaded with such a drug and/or cell therapeutic agent.
- Disclosed is a method for preparing bacterial cell-derived microvesicles for the treatment and/or diagnosis of cancer. In the preparation method the bacterial cell-derived microvesicles may be microvesicles that are spontaneously shed from bacteria, or artificial microvesicles.
- A method for preparing shedding microvesicles for the treatment or diagnosis of cancer may comprise the following steps: adding a drug to a suspension of bacteria or transformed bacteria to give a bacterial suspension containing the drug; and isolating shedding microvesicles loaded with the drug from the bacterial suspension.
- A method for preparing shedding microvesicles for the treatment or diagnosis of cancer may comprise the following steps: isolating shedding microvesicles from a culture of bacteria or transformed bacteria; and incubating a suspension of the isolated microvesicles with a drug. This method may further comprise isolating shedding microvesicles loaded with the drug for the treatment or diagnosis of cancer.
- A method for preparing artificial microvesicles for the treatment or diagnosis of cancer may comprise the following steps: mixing a suspension of bacteria or transformed bacteria with a drug to give a bacterial suspension containing the drug; constructing artificial microvesicles using a process selected from the group consisting of extrusion, ultrasonication, disruption, homogenization, freeze-thawing, electroporation, mechanical degradation, and chemical treatment of the bacterial suspension; and isolating the artificial microvesicles.
- A method for preparing artificial microvesicles for the treatment or diagnosis of cancer may comprise the following steps: constructing artificial microvesicles using a process selected from the group consisting of extrusion, ultrasonication, disruption, homogenization, freeze-thawing, electroporation, mechanical degradation, and chemical treatment of suspension of bacteria or transformed bacteria; and isolating the artificial microvesicles; and incubating a suspension of the isolated microvesicles with a drug. This method may further comprise isolating artificial microvesicles loaded with the drug for the treatment or diagnosis of cancer from the bacterial suspension.
- The preparation method may further comprise sterilizing the shedding or artificial microvesicles for the treatment or diagnosis of cancer using a process selected from the group consisting of antibiotic treatment, UV exposure, gamma ray exposure, and filtration.
- Also disclosed is a pharmaceutical composition comprising bacterial cell-derived microvesicles loaded with a drug therapeutic or diagnostic for cancer.
- Also disclosed is a pharmaceutical composition comprising bacterial cell-derived microvesicles loaded with a drug therapeutic or diagnostic for cancer, the bacterial cell being transformed to target cancer cells or tissues.
- Also disclosed is a method for delivering a drug therapeutic and/or diagnostic for cancer to a cancer cell or cancer tissue, comprising using bacterial cell-derived microvesicles loaded with the drug, the bacterial cell being transformed to target cancer cells or tissues.
- Also disclosed is a kit for the diagnosis of a disease, comprising bacterial cell-derived microvesicles loaded with a substance diagnostic for the disease.
- As mentioned above, the invention provides bacterial cell-derived spontaneously shedding microvesicles for use in the treatment of cancer, wherein
- (a) the microvesicles are administered simultaneously or sequentially with a drug that is suppressive of the toxicity of endotoxin of the microvesicles;
- (b) the microvesicles are loaded with a drug that is suppressive of the toxicity of endotoxin of the microvesicles; and/or
- (c) the bacteria are transformed to have a modified gene involved in formation of an endotoxin so that the microvesicles are mitigated in toxicity.
- The microvesicles according to the claims may be loaded with a protein as an active ingredient. The protein may be derived from Gram-negative or Gram-positive bacteria. The microvesicles according to the claims may be loaded with a nucleic acid as an active ingredient. The nucleic acid may be derived from Gram-negative or Gram-positive bacteria. The microvesicles according to the claims may be loaded with a lipid as an active ingredient. The lipid may be derived from Gram-negative or Gram-positive bacteria. The microvesicles according to the claims may be loaded with two or more components selected from a protein, a nucleic acid and a lipid as active ingredients. Also disclosed is the use of a nanoparticle therapeutic agent reconstituted with a protein in treating cancer, the protein being a component of bacterial cell-derived microvesicles.
- Also disclosed is the use of a nanoparticle therapeutic agent loaded with a nucleic acid in treating cancer, the nucleic acid being a component of bacterial cell-derived microvesicles.
- Also disclosed is the use of a nanoparticle therapeutic agent reconstituted with a lipid in treating cancer, the lipid being a component of bacterial cell-derived microvesicles.
- Also disclosed is the use of a nanoparticle therapeutic agent loaded or reconstituted with two or more components of bacterial cell-derived microvesicles in treating cancer.
- Also disclosed is a method for treating cancer, comprising administering a component of the bacterial cell-derived microvesicles. In one aspect of the present disclosure, the proteins, present as one of the components of the bacterial cell-derived microvesicles, include water-soluble proteins, lipid-soluble proteins, or membrane proteins, but are not limited thereto.
- In another aspect of the present disclosure, the nucleic acids may include DNA and RNA, but are not limited thereto.
- The bacterial cell-derived spontaneously shedding microvesicles for use in accordance with the present invention can be applied to the treatment of cancer, with a decrease in the side effects of conventional drugs, whereby the agony and inconvenience of the patient in the course of treatment can be reduced.
- Conventional anticancer agents act non-specifically on proliferating cells, causing side effects upon exertion of their cytotoxicity on normal cells. In addition, conventional administration methods allow anticancer agents to be delivered to not only cancer cells or tissues, but also non-cancerous organs, thus causing significant side effects. With an increase in the senescent population, cancer in elderly persons is rising as a social problem. Abnormality of immune functions which lose the capacity of controlling the growth of cancer mainly accounts for the onset and progression of cancer, but there are only rare cases in which cancer is treated by enhancing the defense mechanism of effectively suppressing the growth of cancer.
- The bacterial cell-derived spontaneously shedding microvesicles for use according to the present invention can be used in effectively suppressing the growth of cancer. Once they are loaded with a targeting molecule, microvesicles derived from bacterial cells according to the claims, whether or not transformed, can be directed towards cancer vessels, cells or tissues, thus minimizing the adverse effects resulting from the erroneous targeting of microvesicles. In addition, when a drug such as an anticancer agent, an anti-inflammatory agent, etc., is loaded thereto or encapsulated thereinto, the microvesicles can deliver the drug accurately and thus maximizes the therapeutic effect of the drug, while neither being directed toward off-target cells, nor causing side effects. In addition, microvesicles that are reduced in toxicity and improved in therapeutic capacity can be prepared using a genetic, chemical or mechanical process disclosed herein.
- Another advantage of the bacterial cell-derived spontaneously shedding microvesicles for use according to the present invention is the mass production thereof, together with the applicability thereof to a wide spectrum of subjects.
- Furthermore, so long as it is expressed by bacterial cells, any targeting molecule, therapeutic substance or diagnostic substance may be loaded on or within bacterial cell-derived microvesicles without purification. The loaded substances can perform their inherent functions effectively.
-
-
FIG. 1 is a TEM image showing microvesicles constructed from the Gram-negative bacterium E. coli by extrusion. -
FIG. 2 is a graph showing the inhibition of shedding microvesicles derived from Gram-negative bacterium E. coli (E. coli MV) against the growth of cancer tissues (tumor volume) in animal models of colon cancer. -
FIG. 3 is a graph showing the inhibition of shedding microvesicles derived from Gram-negative bacterium P. aeruginosa (P. aeruginosa MV) against the growth of cancer tissues (tumor volume) in animal models of colon cancer. -
FIG. 4 is a graph showing the inhibition of shedding microvesicles derived from Gram-negative bacterium S. enteritidis (S. enteritidis MV) against the growth of cancer tissues (tumor volume) in animal models of colon cancer. -
FIG. 5 is a graph showing the inhibition of shedding microvesicles derived from Gram-positive bacterium S. aureus (S. aureus MV) against the growth of cancer tissues (tumor volume) in animal models of colon cancer. -
FIG. 6 is a graph showing the inhibition of shedding microvesicles derived from Gram-positive bacterium L. acidophilus (L. acidophilus MV) against the growth of cancer tissues (tumor volume) in animal models of colon cancer. -
FIG. 7 is a graph showing anticancer effects of shedding microvesicles (E. coli MV) derived from wild-type E. coli and mutant E. coli transformed to have reduced toxicity of lipopolysaccharides on the growth of cancer tissues (tumor volume) in animal models of colon cancer. -
FIG. 8 is a graph showing anticancer effects of shedding microvesicles (S. aureus MV) derived from wild-type S. aureus and mutant S. aureus transformed to have reduced toxicity of lipoteichoic acid on the growth of cancer tissues (tumor volume) in animal models of colon cancer. -
FIG. 9 is a graph showing anticancer effects of shedding microvesicles (E. coli MV) derived from mutant E. coli transformed to have reduced toxicity of lipopolysaccharides on the growth of cancer tissues (number of colony) in animal models of metastasized melanoma. -
FIG. 10 is a graph showing anticancer activity upon coadministration of shedding microvesicles (MV) derived from mutant E. coli transformed to have reduced toxicity of lipopolysaccharides, and aspirin (ASA) to animal models of colon cancer. -
FIG. 11 shows images of doxorubicin loaded to green fluorescent (DiO)-labeled shedding microvesicles derived from mutant E. coli transformed to have reduced toxicity of lipopolysaccharides (mutant E. coli MV). -
FIG. 12 is a graph showing the anticancer activity of doxorubicin (Doxo)-loaded shedding microvesicles (MV+Doxo) derived from mutant E. coli transformed to have reduced toxicity of lipopolysaccharides against a mouse colon 26 cell line. -
FIG. 13 is a graph showing the effect of polymyxin B (PMB) on the side effect (death caused by systemic inflammation) of E. coli-derived shedding microvesicles (E. coli MV). -
FIG. 14 is a graph showing the effects of microvesicles derived from wild-type E. coli (wild-type MV) and mutant E. coli transformed to have reduced toxicity of lipopolysaccharides (mutant MV) on the side effect (death caused by systemic inflammation) of E. coli-derived shedding microvesicles. -
FIG. 15 is a graph showing a change in the number of platelets after microvesicles derived from mutant E. coli transformed to have reduced toxicity of lipopolysaccharides (mutant E. coli MV) are intravenously injected. -
FIG. 16 is a graph showing a change in the level of D-dimer after microvesicles derived from mutant E. coli transformed to have reduced toxicity of lipopolysaccharides (mutant E. coli MV) are intravenously injected. -
FIG. 17 is a view showing hemolysis observed on a blood agar plate after microvesicles derived from mutant E. coli transformed to have reduced toxicity of lipopolysaccharides (mutant E. coli MV) are incubated on the plate. -
FIG. 18 is graph showing side effects (IL-6 release from inflammatory cells) of shedding microvesicles (S. aureus MV) derived from wild-type S. aureus and mutant S. aureus transformed to have reduced toxicity of lipoteichoic acid. -
FIG. 19 is a graph showing the effect of the coadministration of aspirin (ASA) on the side effect (WBC count, indicative of systemic inflammation) of microvesicles derived from mutant E. coli transformed to have reduced toxicity of lipopolysaccharides (MV) in animal models of colon cancer. -
FIG. 20 shows images of cancer cells to which fluorescent beads with a size of 100 nm are delivered by shedding microvesicles derived from mutant E. coli transformed to have reduced toxicity of lipopolysaccharides (mutant E. coli MV), in animal models of colon cancer. -
FIG. 21 is a graph showing the inhibition of OmpA, a major outer membrane protein of bacterial cell-derived shedding microvesicles against the growth of cancer tissues (tumor volume) in animal models of colon cancer. -
FIG. 22 is a graph showing the inhibition of shedding microvesicles (E. coli MV) derived from OmpF-knockout (OmpF-/-) mutant E. coli and from the wild-type (WT) against the growth of cancer tissues (tumor volume) in animal models of colon cancer. -
FIG. 23 is a view showing the presence of OmpA in liposomes after OmpA, a component of bacterial cell-derived microvesicles, was reconstituted to liposomes serving as a nanoparticle carrier. - The present invention provides bacterial cell-derived spontaneously shedding microvesicles for use in the treatment of cancer, wherein
- (a) the microvesicles are administered simultaneously or sequentially with a drug that is suppressive of the toxicity of endotoxin of the microvesicles;
- (b) the microvesicles are loaded with a drug that is suppressive of the toxicity of endotoxin of the microvesicles; and/or
- (c) the bacteria are transformed to have a modified gene involved in formation of an endotoxin so that the microvesicles are mitigated in toxicity.
- The bacteria useful in the present invention may be Gram-negative or Gram-positive. Exemplary among the Gram-negative bacteria are E. coli, Pseudomonas aeruginosa, and Salmonella sp. Examples of the Gram positive bacteria include Staphylococcus aureus and Lactobacillus acidophilus, but are not limited thereto.
- As used herein, the term "bacteria" refers to naturally occurring bacteria or transformed bacteria. More specifically, the term "transformed bacteria," as used herein, is intended to include, but is not limited to, bacteria that have been transformed to have reduced toxicity, for example, have a modified endotoxin gene; bacteria that have been transformed to express a substance necessary for targeting cells or tissues of interest, for example cancer vessels, cancer tissues or cancer cells; and bacteria that have been transformed to express a substance necessary for cell membrane fusion with a target cell, therapy and/or diagnosis of a disease of interest; and bacteria that have been transformed to both upregulate a substance of interest and downregulate a substance of interest.
- Further, the bacteria may be transformed two or more times by treating the cells with a substance, or by introducing a foreign gene into the cells.
- In one embodiment of the present invention, the bacteria may be transformed to downregulate at least one protein involved in toxicity.
- In one embodiment of the present invention, the transformed bacteria may be adapted to express one or more substances selected from the group consisting of, but not limited to, a cell adhesion molecule, an antibody, a targeting protein, a cell membrane fusion protein, and a fusion protein thereof.
- As used herein, the term "bacterial cell-derived microvesicles" is limited to "shedding microvesicles", which are spontaneously secreted from bacteria. Excluded from the invention are "artificial microvesicles," which are artificially synthesized using a genetic, chemical or mechanical process.
- The term "bacterial cell-derived microvesicles," as used herein, refers to sub-cell sized vesicles, the interior of which is separated from the outside environment only by a lipid bilayer membrane and which have plasma membrane lipids, plasma membrane proteins, nucleic acid, and bacterial components.
- The spontaneously shedding microvesicles for use according to the present invention may be constructed using one of the following illustrative, non-limiting methods.
- (1) Culturing bacteria or transformed bacteria, and filtering and ultracentrifuging the culture to give shedding microvesicles.
- (2) Treating bacteria or transformed bacteria with an antibiotic, and filtering and ultracentrifuging the culture to give shedding microvesicles. The antibiotic is not imparted with particular limitations, and includes gentamycin, ampicillin, and kanamycin.
- In one embodiment of the present invention, the bacterial cell-derived microvesicles according to the claims may further comprise components in its membrane other than those derived from the cell membrane of the bacteria.
- The components other than those derived from the cell membrane may include targeting molecules, fusogens, which are necessary for membrane fusion with target cells, cyclodextrins, and polyethylene glycol. In addition, the components other than those derived from the cell membrane may be added using a variety of methods, including chemical modification of cell membranes.
- For example, membrane components of the bacterial cell-derived microvesicles may be chemically modified with thiol (-SH) or amine (-NH2) groups or by chemically bonding polyethylene glycol to the membrane.
- The method for preparing bacterial cell-derived microvesicles disclosed herein may further comprise the chemical modification of membrane components.
- The microvesicles according to the claims may comprise a drug that functions to neutralize the toxicity of endotoxin of the microvesicles themselves. In this regard, the drug may be loaded to the microvesicles. The drug may function to suppress the toxicity of endotoxins, and may be polymyxin B.
- The microvesicles according to the claims may further comprise a drug that enhances anticancer activity. In this regard, the drug may be loaded to the microvesicles. The drug useful in the present invention includes a drug suppressive of the immune response of Th17 (T helper 17), a drug suppressive of the production or activity of interleukin 6 (IL-6), a drug suppressive of the production or activity of vascular endothelial growth factor (VEGF), a drug suppressive of STAT3 (signal transducer and activator of transcription 3) signaling, an anticancer agent, a nanoparticle therapeutic agent loaded with such a drug, and a cell therapeutic agent for cancer. The drug suppressive of the immune response of Th17 may be aspirin, and the drug suppressive of the formation or activity of VEGF may function to interrupt with VEGF receptor-mediated signaling. An anticancer agent-loaded nanoparticle may be a liposome such as DOXIL.
- The microvesicles according to the claims may be present in a pharmaceutical composition which may comprise a pharmaceutically acceptable carrier, for example, saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, a dextrose solution, a maltodextrin solution, glycerol, ethanol, liposome, or a combination thereof. If necessary, the pharmaceutical composition may further comprise a typical additive such as an antioxidant, a buffer, etc. Furthermore, the pharmaceutical composition may be formulated into injections such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules or tablets, with the aid of a diluent, a dispersant, a surfactant, a binder and/or a lubricant. Moreover, the pharmaceutical composition may be formulated into suitable dosage forms according to a method that is well known in the art or the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA. No particular limitations are imparted to the formulations of the pharmaceutical composition. Preferably, the pharmaceutical composition may be formulated into injections or inhalable forms.
- No particular limitations are imparted to the administration of the pharmaceutical composition. The pharmaceutical composition may be administered orally or parenterally such as intravenously, subcutaneously, intraperitoneally, via inhalation, or topically. The amount of the active ingredient in the pharmaceutical composition may vary depending on various factors including a patient's weight, age, gender and health condition, diet, the time of administration, the route of administration, the rate of excretion, the severity of disease, and the like. The term "daily dose" means an amount of the therapeutically effective ingredient which is sufficient to reduce the condition of disease when it is administered to a subject in need thereof. A suitable dose of the active ingredient in the pharmaceutical composition may depend on the kind of the loaded compounds, disease severity, and the condition of a subject in need of treatment, and can be determined by those skilled in the art. For example, the suitable dose of the composition may vary depending on a patient's weight, age, gender and health condition, the route of administration, and the severity of disease, and generally ranges from 0.1 to 1000 mg/day, and preferably from 1 to 500 mg/day, based on adult patients with a weight of 70kg. The total effective amount of the pharmaceutical composition can be administered to patients in a single dose or can be administered by a fractionated treatment protocol, in which multiple doses are administered over a more prolonged period of time.
- As used herein, the term "subject" refers to an animal in need of the treatment of cancer, including a human, or non-human mammals such as primates, mice, rats, dogs, cats, horses, cows, etc.
- As used herein, the term "cancer" refers to a group of different diseases, which are characterized by unregulated cell growth and infiltration to neighboring tissues due to the disruption of programmed cell death. A target to be treated according to the present invention may be selected from a cancer selected from the group consisting of, but not limited to, carcinoma originating from epithelial cells, such as lung cancer, larynx cancer, stomach cancer, large intestine/rectal cancer, liver cancer, gallbladder cancer, pancreatic cancer, breast cancer, uterine cervical cancer, prostate cancer, kidney cancer, skin cancer, etc., sarcoma originating from connective tissue cells, such as bone cancer, muscle cancer, fat cancer, fibrous cell cancers, etc., blood cancer originating from hematopoietic cells, such as leukemia, lymphoma, multiple myeloma, etc., and neuroma, a tumor of nervous tissues.
- As mentioned above, the bacterial cell-derived microvesicles according to the claims may be loaded with a drug which functions to neutralize the side effects of the microvesicles themselves.
- The side effects that the bacterial cell-derived microvesicles themselves retain can be reduced in various manners as follows.
- (1) Microvesicles may be prepared from bacteria cells which have been genetically transformed to have reduced toxicity of endotoxin. For example, bacteria transformed to mitigate the toxicity of the lipopolysaccharides that mediate the immune response of host cells (msbB mutant), or the toxicity of lipoteichoic acid (LTA) (LTA mutant), can be used as a source of microvesicles.
- (2) A drug suppressive of the toxicity of endotoxins may be employed. This drug may be exemplified by polymyxin B. The drug may be administered in combination with the bacterial cell-derived microvesicles, or loaded to the microvesicles by constructing them from a bacteria culture containing the drug.
- The side effects can additionally be reduced by a drug functioning as an anti-inflammatory and/or anti-coagulant agent. The drug may include aspirin. When administered in combination with the bacterial cell-derived microvesicles, aspirin prevents the microvesicle-induced side effects such as inflammatory responses, blood coagulation, etc. Alternatively, microvesicles may be constructed from bacteria that have been cultured in the presence of the drug.
- The side effects may additionally be reduced by chemically modifying membrane components of the bacterial cell-derived microvesicles. For example, the membrane components may be chemically modified with thiol or amine groups or by bonding polyethylene glycol to the membrane.
- Bacterial infection, which may occur upon the administration of bacterial cell-derived microvesicles, may be prevented by sterilization. For example, the bacterial cell-derived microvesicles are sterilized using UV or gamma radiation or through filtration to kill or remove bacteria.
- These examples do not limit the additional methods of reducing the side effects of the bacterial cell-derived microvesicles and may be employed individually or in combination.
- In another embodiment of the present invention, microvesicles according to the claims loaded with a drug that potentiates anticancer activity may be used. This drug may be as described above.
- In another embodiment of the prevent invention, the microvesicles according to the claims may be administered to a subject, in combination with a drug suppressive of side effects of microvesicles and/or a drug potentiating anticancer activity, a nanoparticle therapeutic agent loaded with such a drug, and a cell therapeutic agent.
- The nanoparticle therapeutic agent is a particle with a size of 10 nm ∼ 10 µm, and examples thereof include, but are not limited to, liposomes, dendrimers, polymers, and microvesicles
- As used herein, the term "loading" refers to, but not limited to, a process of displaying a substance of interest on the surface of the bacterial cell-derived microvesicles or of encapsulating the substance within the microvesicles.
- Also disclosed is a method for the preparation of shedding microvesicles for cancer therapy or diagnosis which comprises: adding a drug to a suspension of bacteria or transformed bacteria to give a bacterial suspension containing the drug; and isolating shedding microvesicles loaded with the drug from the bacterial suspension; or isolating shedding microvesicles from a culture of bacteria or transformed bacteria; and incubating a suspension of the isolated microvesicles with a drug. This method may further comprise isolating shedding microvesicles loaded with the drug for cancer therapy or diagnosis.
- The method for the preparation of shedding microvesicles for cancer therapy or diagnosis disclosed herein may further comprise sterilizing the shedding microvesicles using a process selected from the group consisting of antibiotic treatment, UV exposure, gamma ray exposure, and filtration.
- The preparation method disclosed herein may further comprise isolating sub-cell sized, drug-loaded microvesicles.
- This isolating step may be carried out using a process selected from the group consisting of a density gradient, ultracentrifugation, filtration, dialysis and free-flow electrophoresis.
- The preparation method may further comprise removing microvesicles whose membranes are topologically different from those of the bacterial cells of origin. After construction of microvesicles, only those microvesicles that have the same membrane topology as that of the source cells may be selected according to purposes. Using antibodies recognizing cytoplasmic domains of membrane proteins, microvesicles in which the cytoplasmic domains are exposed to the outside can be removed. That is, the microvesicles in which the plasma membrane is turned inside out are removed, and only the microvesicles in which the extracellular domains of membrane proteins are positioned so as to be directed towards the outside remain.
- No particular limitations are imparted to the substance to be loaded to the bacterial cell-derived microvesicles according to the claims. For example, the substance may be one used for therapy and/or diagnosis, or a protein expressed by the bacteria or transformed bacteria themselves. If necessary, the loading substance may not be native to the cells, but may be a foreign material. That is to say, the therapeutic and/or diagnostic substance may be at least one derived from the bacteria or introduced from the outside of the bacterial cells. In addition, the substance may be loaded to the surface of microvesicles using, but not limited to, physical, chemical and/or biological methods.
- The bacterial cell-derived microvesicles according to the claims may be loaded with the various therapeutic or diagnostic substances in various manners as follows.
- First, microvesicles can be prepared from cells which have already been loaded with a therapeutic or diagnostic substance of interest. For example, when cells are cultured in a medium containing the therapeutic or diagnostic substance of interest, they may contain the substance therein. Alternatively, the substance may be introduced into cells by electroporation.
- Also, microvesicles which shed from the cells containing the substance are loaded with the substance.
- In another alternative, shedding microvesicles may be loaded with a substance of interest after they are formed. For example, the loading can be achieved by electroporating the substance into already prepared shedding microvesicles.
- However, it should be appreciated by those skilled in the art that the loading of a substance of interest into microvesicles is not limited to the above-illustrated methods.
- Among the therapeutic substances useful in the present invention are anticancer agents, anti-inflammatory agents, angiogenesis inhibitors, peptides, proteins, toxins, nucleic acids, beads, microparticles and nanoparticles, but the present invention is not limited thereto.
- Examples of the nucleic acids include DNA, RNA, aptamers, LNA (locked nucleic acid), PNA (peptide nucleic acid), and morpholinos, but are not limited thereto.
- Illustrative, non-limiting examples of the nanoparticles include iron oxide, gold, carbon nanotubes, and magnetic beads, but are not limited thereto.
- A diagnostic substance may be a fluorophore. For example, the fluorophore may be a fluorescent protein or quantum dot (Qdot).
- In another embodiment of the present invention, the therapeutic substance may be one or more anticancer agents.
- The microvesicles for use according to the present invention may be guided to specific cells or tissues. The specific tissues may include, but are not limited to, blood vessels, cancer and inflammatory tissues.
- Disclosed is a method for delivering a drug therapeutic and/or diagnostic for a disease, a nanoparticle therapeutic agent loaded with the drug, and a cell therapeutic agent, comprising using bacterial cell-derived microvesicles loaded with the therapeutic and/or diagnostic drug.
- Disclosed is a method for delivering a substance therapeutic and/or diagnostic for a disease, a nanoparticle therapeutic agent loaded with a substance therapeutic and/or diagnostic for a disease, and a cell therapeutic agent, comprising using microvesicles loaded with the therapeutic and/or diagnostic substance, said microvesicles being derived from bacteria transformed to target a cell or tissue of interest.
- A substance therapeutic or diagnostic for a disease, a nanoparticle therapeutic agent loaded with a substance therapeutic and/or diagnostic agent, and a cell therapeutic agent can be delivered with the aid of the microvesicles disclosed herein.
- Two or more different therapeutic or diagnostic substances may be delivered to specific cells or tissues.
- Two or more different microvesicles selected from the group consisting of a microvesicle loaded with one therapeutic or diagnostic substance, a microvesicle loaded with two or more different therapeutic or diagnostic substances, and a combination thereof may be used to deliver the therapeutic or diagnostic substance(s). For example, two or more different microvesicles may be administered simultaneously.
- Also disclosed is a kit for the diagnosis of a disease, comprising bacterial cell-derived microvesicles loaded with a diagnostic substance. The diagnostic substance may be selected from the group consisting of a primer, a probe, an antisense nucleic acid, and an antibody.
- In the present invention, microvesicles according to the claims derived from cells targeting a specific tissue or from transformed cells expressing a targeting protein may be employed. In addition, the microvesicles according to the claims may be derived from transformed cells expressing a fusogen.
- It is known that the blood cells, that is, monocytes, lymphocytes, neutrophils, eosinophils, basophils, and platelets, myeloid-derived suppressor cells, and stem cells found in bone marrow, blood, and adipose tissues are guided to cancerous and inflammatory tissues. Microvesicles derived from bacteria which are transformed to express a protein binding selectively to a substrate expressed on a specific cell or tissue can be guided to the specific cell or tissue. After being loaded with therapeutic or diagnostic substances, microvesicles constructed from such bacterial cells can be used to deliver the substances to target cells, tissues or blood.
- There are a variety of plasma membrane proteins that are involved in the guidance of immune/inflammatory cells and stem cells to specific tissues. For example, cell adhesion molecules including integrins such as LFA-1 (leukocyte function-associated antigen-1) and Mac-1 (macrophage-1 antigen) are present on the surface of monocytes. These cell adhesion molecules can bind to other cell adhesion molecules, such as ICAM-1 (intercellular adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1), on vascular cells. Interaction between LFA-1 and ICAM-1 allows monocytes to pass through vascular endothelial cells so that the monocytes can be guided to inflammatory or cancerous tissues.
- When transformed to express plasma membrane proteins specific for cancer or tissues of interest on the surface of bacterial cell-derived microvesicles, the microvesicles can be guided to specific tissues, such as vascular tissues, cancerous or tumorous tissues, etc. By way of example, ERBB2 is overexpressed on the surface of breast cancer cells. Microvesicles derived from bacteria which have been transformed to express a fusion protein composed of a bacterial transmembrane protein and an antibody specific for the membrane protein ERBB2 can be allowed to target breast cancer tissues. Further, bacterial cell-derived microvesicles can be guided toward large intestine cancer, pancreatic cancer and lung cancer tissue if they are transformed to express a fusion protein in which an antibody recognizing a carcinoembryonic antigen (CEA) abundantly found in the cancer tissues is fused to a bacterial transmembrane protein.
- Bacterial cell-derived microvesicles retain almost the same membrane components as those of the bacterial cells of origin, so that they can be directed toward specific tissues or cells that the bacteria target. If necessary, a nuclease may be employed during the construction of microvesicles to remove nucleic acids unnecessary for the delivery of a therapeutic or diagnostic substance from the microvesicles.
- Bacterial cell-derived microvesicles can be readily loaded with various therapeutic or diagnostic substances to be delivered. Hence, microvesicles may be used for mono- or combined therapy or diagnosis or both of therapy and diagnosis (theragnosis, pharmacodiagnosis). In this context, the substances to be delivered may be present inside the microvesicles when encapsulated, within the lipid bilayer when at least partially buried or embedded therein like a transmembrane protein, or on the surface of the microvesicles.
- From bacterial cells, microvesicles can be artificially constructed in various sizes like liposomes. Thanks to the EPR (Enhanced Permeability and Retention) effect, generally, molecules with a size of 100 nm or greater may accumulate in cancer tissue for a longer period of time than they do in normal tissues. Accordingly, a drug loaded to microvesicles with a size of 100 nm or greater is advantageous in diagnosis and therapy because it can stay much longer in cancer tissue, thereby enhancing a therapeutic or diagnostic effect. On the other hand, when inhaled, only particles with a size of 1 µm or smaller are allowed to reach the alveoli due to the pulmonary structure. A substance, for example, an inflammation inhibitor for the treatment of asthma, can be delivered to lung tissue if it is loaded to microvesicles which are smaller than 1 µm in size. As described, various sizes of microvesicles may be constructed depending on the tissue to which the loaded substance is to be applied. Preferably, the microvesicles for use according to the present invention range in size from 10 nm to 10 µm.
- When a therapeutic substance loaded to the microvesicles according to the claims is administered to a "subject", an immunosuppressant may be used together therewith.
- Microvesicles according to the claims may be constructed from all kinds of bacterial cells, for example, bacteria that can be directed to a target, such as specific cells or tissues, by transformation. Microvesicles may be constructed from bacterial cells which are directed toward the specific tissue. Also, when constructed from cells in which proteins directed toward specific tissues are upregulated and/or proteins involved in non-specific guidance are downregulated, microvesicles can be effectively used to deliver a therapeutic or diagnostic substance to, for example, blood vessels, cancer tissues, or inflammatory tissues.
- The transformation of bacterial cells can be achieved using typical methods known in the art, for example, by stimulating the cells or introducing a foreign gene into the bacterial cells to modify, e.g., upregulate or downregulate, the expression of proteins of interest. A specific stimulus may induce a change in the expression of a protein of interest. The introduction of a foreign gene may induce the expression or inhibition of a protein of interest. In this context, plasmid DNA, RNA or a phage is introduced into cells using electroporation, microinjection, ultrasound mediation or other methods known in the art.
- After bacteria are transformed to express a protein or an antibody capable of binding to cancer cells, tissues or vessels or inflammatory tissues, solely or as a fusion protein on the surface thereof, microvesicles can be constructed from the bacterial cells. In addition, microvesicles may be prepared from bacterial cells expressing a therapeutic and/or diagnostic substance or bacterial cells transformed to express a therapeutic and/or diagnostic substance. Moreover, microvesicles may be prepared from bacterial cells expressing a combination of the above substances or bacterial cells transformed to express a combination of the above substances. To suppress the expression of specific protein, antisense RNA, LNA, PNA, and the like can be used. When microvesicles constructed from bacterial cells are directed toward two targets, the bacterial cells may be transformed in such a way that the expression of one or more specific proteins is inhibited to reduce the guidance of the cells to one of the two targets. Hence, the specificity in the delivery of the substance for microvesicles derived from the transformed cells is enhanced. Alternatively, bacterial cells which have undergone two or more rounds of transformation may be used. For example, primary transformants may be subjected to secondary transformation before being used as a source for constructing microvesicles.
- The substance useful in the present invention may include, but is not limited to, a substance that bacteria or transformed bacteria express or a foreign substance that the bacteria do not express.
- For use in the present invention, a therapeutic substance may be loaded to microvesicles according to the claims or may be administered in combination with microvesicles according to the claims according to needs and purposes.
- In one embodiment of the present invention, the therapeutic substance may be administered as it is or as a complex with a nanoparticle therapeutic agent or cell therapeutic agent, in combination with microvesicles according to the claims.
- As therapeutic substances which can be loaded to the microvesicles according to the claims or to the nanoparticle or cell therapeutic agent, various materials including proteins or peptides, nucleic acids, lipids and metabolites, all being derived from nucleated, mammalian cells, may be used without limitation.
- Examples of the loadable proteins or peptides useful in the present invention include, but are not limited to, growth factors, such as VEGF, EGF (epidermal growth factor), etc., cytokines such as IL-1, IFN-γ (interferon-gamma), IL-10, etc., antibodies, receptors, and fluorescent proteins. The proteins or peptides may be expressed within cells or displayed on plasma membranes. Also, their entirety or active sites may be expressed solely or as fusion proteins. It is known that the activity of proteins or peptides displayed on microvesicles is higher than when they exist solely within cells as a result of the higher local concentration. Proteins or peptides on microvesicles may act as ligands to trigger signaling or as antagonists to inhibit the function of various ligands.
- Examples of the nucleic acids loadable to the microvesicles or the nanoparticle or cell therapeutic agent according to the present invention include DNA, miRNA (microRNA), siRNA (small inferring RNA), antisense RNA, and sense RNA, but are not limited thereto. These nucleic acids may be used to evoke sense effects, antisense effects, RNA interference, or inhibition of protein functions.
- As the foreign therapeutic or diagnostic substance loadable to the microvesicles or the nanoparticle or cell therapeutic agent, anticancer agents, anti-inflammatory agents, angiogenesis inhibitors, peptides, proteins, toxins, nucleic acids, beads, microparticles and nanoparticles may be used without limitation.
- An anticancer agent is a generic term of a drug used to suppress the growth and metastasis of cancer. Most anticancer agents act to block the replication, transcription and/or translation of cancer cells. No particular limitations are imparted on the kinds of anticancer agents useful in the present invention. Under the general principle in which the kinds of cancer cells, absorption rates of anticancer agents (the duration of treatment, the route of administration, etc.), positions of tumor, sizes of tumor, etc. are taken into consideration, anticancer agents may be selected. Examples of the anticancer agents useful in the present invention include DNA alkylating agents, such as mechlorethamine, chlorambucil, phenylalanine, mustard, cyclophosphamide, ifosfamide, carmustine (BCNU), lomustine (CCNU), streptozotocin, busulfan, thiotepa, cisplatin and carboplatin, anti-cancer antibiotics, such as dactinomycin (actinomycin D), doxorubicin (adriamycin), epirubicin, idarubicin, mitoxantrone, plicamycin, mitomycin and C Bleomycin, and plant alkaloids, such as vincristine, vinblastine, paclitaxel, docetaxel, daunorubicin, taxol, oncovin, prednisone, cisplatin, herceptin, rituximab, etoposide, teniposide, topotecan and iridotecan. Also, radioactive substances known in the art may be used. However, the anticancer agents useful in the present invention are not limited to the examples.
- Further, the anti-inflammatory agent loadable to the microvesicles according to the claims or the nanoparticle or cell therapeutic agent is selected from the group consisting of, but not limited to, dexamethasone, indomethacin, ibuprofen, clobetasol propionate, diflorasone diacetate, halobetasol propionate, amcinonide, fluocinonide, mometasone furoate, desoximetasone, diclofenac and piroxicam.
- As used herein, the term "angiogenesis inhibitor" refers to a drug that functions to suppress the growth of new blood vessels from preexisting vessels. Most angiogenesis inhibitors have the function of suppressing the growth and metastasis of cancer, and inflammatory reactions. No particular limitations are imparted to the kinds of the angiogenesis inhibitors available as the therapeutic substance useful in the present invention.
- The therapeutic substance loaded to the microvesicles according to the claims or the nanoparticle or cell therapeutic agent may include proteins or peptides. For example, RNase A, growth factors, such as VEGF and EGF, cytokines, such as IL-1, IFN-gamma and IL-10, antibody therapeutics, DNase, and various proteins or peptides suppressing the growth and metastasis of cancer cells and inflammatory responses may be employed without limitations.
- Also, the therapeutic substance loaded to the microvesicles according to the claims or the nanoparticle or cell therapeutic agent may include toxins. The term "toxin" refers to a poisonous substance produced within living cells or organisms, which is capable of causing a disease on contact with or adsorption by body tissues. Using a toxin, cell death can be induced. No particular limitations are imparted to the kind of toxin available as the therapeutic substance useful in the present invention.
- Representative among the nucleic acids loadable to the microvesicles according to the claims or the nanoparticle or cell therapeutic agent are DNA, miRNA, siRNA, antisense RNA, sense RNA, and aptamers. Also, nucleic acid analogs such as LNA, PNA, and morpholinos may be loaded to the microvesicles or the nanoparticle or cell therapeutic agent, but not limited thereto. These nucleic acids may be used to evoke sense effects, antisense effects, RNA interference, or inhibition of protein functions.
- Also disclosed is that microvesicles loaded with nucleic acids encoding fluorescent proteins or with various fluorescents can be used for diagnosis. When microvesicles designed to target specific cells or tissues are loaded with a plasmid DNA carrying a gene encoding a fluorescent protein and introduced into the body, the fluorescence signal emitted from the fluorescent protein makes it possible to recognize where the target cells or tissues exist. Likewise, fluorescent quantum dots or other various fluorescents may be loaded to microvesicles and used to detect the position of specific cells and tissues within the body. That is, fluorescence generated from target cells or tissues can be used for diagnosis. In addition, fluorescence-emitting quantum dots may be applied to the treatment of diseases because they induce apoptosis.
- Therapeutic or diagnostic substances other than fluorescents, loadable to the microvesicles, may be exemplified by microparticles or nanoparticles. Examples include iron oxide particles, gold particles and carbon nanotubes, but are not limited thereto. Magnetic beads may be used as the therapeutic or diagnostic substance and loaded into the microvesicles. Magnetic particles such as iron oxide may be used as an image contrasting agent for MRI (magnetic resonance imaging). Moreover, nucleic acids or proteins conjugated with nanoparticles may be employed. Diagnostic radioactive substances are also available.
- Two or more different substances can be delivered by the microvesicles according to the claims. For example, the microvesicles according to the claims with two or more different substances simultaneously loaded thereto may be used to deliver the substances. Alternatively, microvesicles according to the claims loaded with different substances individually or in combination are employed in combination so that two or more different substances can be delivered. In order to deliver three different substances, for instance, a first, a second and a third microvesicle according to the claims may be loaded with the three different substances, respectively. On the other hand, a fourth microvesicle according to the claims with two different substances simultaneously loaded thereto and a fifth microvesicle according to the claims with another different substance loaded thereto may be used to deliver the three different substances. The first, the second and the third microvesicles according to the claims may be used simultaneously or sequentially. Likewise, the fourth and the fifth microvesicles according to the claims may be used simultaneously or sequentially.
- There are various methods for isolating microvesicles from other molecules or other cellular components, examples of which include a density gradient, ultracentrifugation, filtration, dialysis, and free flow electrophoresis, but these are not limited thereto.
- A density gradient process, one of the most popular processes for distinguishing materials with different densities, can be applied to the isolation of the microvesicles according to the claims because their densities are different from those of free molecules. For use in the density gradient process, a medium may be selected from among, but not limited to, Ficoll, glycerol, sucrose and OptiPrep™. Microvesicles loaded with or without therapeutic or diagnostic substances may be separated from each other when taking advantage of differences in density therebetween. A density gradient process may be used in combination with centrifugation or electrophoresis. Microvesicles can also be isolated by gel filtration or ultrafiltration. Instead of filtration, dialysis may be adopted to remove small molecules. In addition, free flow electrophoresis is useful for isolating microvesicles.
- According to purpose, microvesicles within a certain size range may be selected before use. The selection of microvesicles within a certain size range may be carried out before, simultaneously or after loading therapeutic or diagnostic substances thereinto.
- Microvesicles in which a part of membrane components have been modified may be constructed. For example, when microvesicles are constructed from a mixture of a fusion protein and cells, the fusion protein may be at least partially exposed on the microvesicles. Microvesicles may be converted into stealth-microvesicles by coating with polyethylene glycol. The addition of cyclodextrin to microvesicles may reduce the non-specific targeting of the microvesicles. Exhibiting both hydrophilicity and hydrophobicity, cyclodextrin, when attached onto the surface of microvesicles, can act to block non-specific binding between lipids. The microvesicles or shedding microvesicles may be chemically modified. For example, after microvesicles are constructed from cells whose membrane or transmembrane proteins are at least in part exposed to the outside, various molecules may be chemically bound to the thiol group of cysteine residues on the exposed region of the protein. Additionally, membrane components of the microvesicles can be modified by chemical biding of various molecules to the amine group within a membrane protein.
- The bacteria useful in the present invention may be Gram-negative or Gram-positive. Exemplary among the Gram-negative bacteria are E. coli, Pseudonomas aeruginosa, and Salmonella sp. Examples of the Gram positive bacteria include Staphylococcus aureus and Lactobacillus aciophilus, but are not limited thereto.
- Examples of the components of the microvesicles include proteins, nucleic acids, and lipids, but are not limited thereto.
- In one embodiment of the present invention, the proteins, present as one of the components of the bacterial cell-derived microvesicles according to the claims, include water-soluble proteins, lipid-soluble proteins, or membrane proteins, but are not limited thereto.
- In another embodiment of the present invention, the microvesicles as defined in the claims may comprise membrane proteins including OmpA, OmpF, OmpC, and flagellin, but not limited thereto.
- In another embodiment of the present invention, the microvesicles as defined in the claims may comprise nucleic acids including DNA and RNA, but not limited thereto.
- In another embodiment of the present invention, the microvesicles as defined in the claims may comprise proteins associated with at least one selected from the group consisting of, but not limited to, a cell adhesion molecule, an antibody, a targeting protein, a cell membrane fusion protein, and a fusion protein thereof
- A better understanding of the present invention may be obtained through the following examples which are set forth to illustrate, but are not to be construed as limiting the present invention.
- Artificial microvesicles were constructed from Gram-negative bacteria by extrusion.
- In this experiment, the Gram-negative bacterium E. coli was employed. E. coli was cultured to an optical density of 1.0 (at 600 nm) in 50 mL of LB broth. The bacteria cells were collected as a pellet after centrifugation at 3,500 x g for 10 min, and the cell pellet was resuspended in PBS (phosphate buffered saline).
- This cell suspension was passed three times through each of membrane filters with a pore size of 10 µm, 5 µm, and 1 µm, in that order. In a 5 mL ultracentrifuge tube, 1 mL of 50 % OptiPrep, 1 mL of 5 % OptiPrep, and 3 mL of the cell suspension effluent from the membrane filters were sequentially placed. Ultracentrifugation at 100,000 × g for 3 hrs formed a layer of microvesicles between 50 % OptiPrep and 5 % OptiPrep.
- The artificial microvesicles constructed from the Gram-negative bacterium were analyzed for properties. The Gram-negative bacterial cell-derived, artificial microvesicles were adsorbed for 3 min to a glow-discharged carbon-coated copper grid. The grid was washed with distilled water, and stained for 1 min with 2 % uranylacetate before observation under a JEM101 electron microscope (Jeol, Japan). The result is shown in
FIG. 1 . As can be seen in the transmission electron microscope images ofFIG. 1 , the microvesicles artificially constructed from bacterial cells by extrusion consisted of a lipid bilayer, and were generally spherical with a size of 10 ∼ 100 nm. - For use in this experiment, microvesicles that were spontaneously shed from Gram-negative bacteria were isolated. The Gram-negative bacteria E. coli, Pseudonomas aeruginosa, and Salmonella enteritidis were used as sources of microvesicles. Bacteria were inoculated into 100 mL of LB in an Erlenmeyer flask and cultured at 37°C for 6 hrs. Of the culture, 8 mL was transferred into 600 mL of LB broth in a 2 L Erlenmeyer flask and cultured at 37°C for 5 hrs to an optical density of 1.5 (at 600 nm). The resulting culture was divided into 500 mL high speed centrifuge tubes before centrifugation at 10,000 x g and 4°C for 20 min. The supernatant was forced to pass once through a membrane filter with a pore size of 0.45 µm, and then concentrated 25-fold using a Quixstand system equipped with a membrane having a molecular weight cut-off of 100 kDa. The concentrate was passed once through a membrane filter with a pore size of 0.22 µm, and divided into 70 mL ultracentrifuge tubes, followed by ultracentrifugation at 150,000 x g and 4°C for 3 hrs to afford bacteria cell-derived shedding microvesicles as a precipitate. This was suspended in PBS.
- The shedding microvesicles derived from E. coli, P. aeruginosa, and S. enteritidis were assayed for anticancer activity. A mouse colon 26 cell line was subcutaneously injected at a dose of 1 × 106 cells into mice, and cultured. After one week, a PBS solution containing 1 µg, or 5 µg of each of the Gram-negative bacterial cell-derived microvesicles was injected at a dose of 100 µl twice a week via the tail vein into the mice which were divided into groups, each consisting of three. On day 23 after the transplantation of cancer cells, the sizes of colon cancer tissue were monitored. The volume of cancer tissue was calculated by the equation V=l x s2/2, wherein 1 is a length of the longest axis of a tumor and s is a length of the axis perpendicular to the longest axis.
- After the subcutaneous transplantation, the volume measurements of colon cancer tissues were as shown in
FIGS. 2 to 4 . The administration of shedding microvesicles derived from E. coli reduced the size of the colon cancer tissue in a dose-dependent manner, compared to the control PBS (FIG. 2 ). A significant reduction in the size of colon cancer tissues was obtained after shedding microvesicles derived from P. aeruginosa were administered (FIG. 3 ). Also, the size of colon cancer tissue was reduced by shedding microvesicles derived from S. enteritidis (FIG. 4 ). - For use in this experiment, microvesicles that were spontaneously shed from Gram-positive bacteria were isolated. The Gram-positive bacteria Staphylococcus aureus and Lactobacillus acidophilus were used as sources of microvesicles. Bacteria were inoculated into 100 mL of a nutrient broth in an Erlenmeyer flask and cultured at 37°C for 6 hrs. Of the culture, 8 mL was transferred into 600 mL of a nutrient broth in a 2 L Erlenmeyer flask and cultured at 37°C for 5 hrs to an optical density of 1.5 (at 600 nm). The resulting culture was divided into 500 mL high speed centrifuge tubes before centrifugation at 10,000 x g and 4°C for 20 min. The supernatant was forced to pass once through a membrane filter with a pore size of 0.45 µm, and then concentrated 25-fold using a Quixstand system equipped with a membrane having a molecular weight cut-off of 100 kDa. The concentrate was passed once through a membrane filter with a pore size of 0.22 µm, and divided into 70 mL ultracentrifuge tubes, followed by ultracentrifugation at 150,000 x g and 4°C for 3 hrs to afford bacteria cell-derived shedding microvesicles as a precipitate. This was suspended in PBS.
- The shedding microvesicles derived from S. aureus and Lactobacillus acidophilus were assayed for anticancer activity. A mouse colon 26 cell line was subcutaneously injected at a dose of 1 × 106 cells into mice, and cultured. After one week, a PBS solution containing 10 µg of each of the Gram-positive bacterial cell-derived microvesicles was injected at a dose of 100 µl twice a week via the tail vein into the mice which were divided into groups, each consisting of three. On day 23 after the transplantation of cancer cells, the sizes of colon cancer tissue were monitored. The volume of cancer tissue was calculated by the equation V=l x s2/2, wherein 1 is a length of the longest axis of a tumor and s is a length of the axis perpendicular to the longest axis.
- After the subcutaneous transplantation, the volume measurements of colon cancer tissues were as shown in
FIGS. 5 and6 . As can be seen in the graphs, a significant reduction in the size of colon cancer tissues was obtained after shedding microvesicles derived from S. aureus (FIG. 5 ) or L. acidophilus (FIG. 6 ) were administered, compared to the control PBS. - The following experiment was carried out with shedding microvesicles which were obtained in the same manner as in Example 2, with the exception that E. coli transformed to have reduced lipopolysaccharide toxicity (msbB mutant) was employed.
- A mouse colon 26 cell line was subcutaneously injected at a dose of 1 × 106 cells into mice, and cultured. After one week, PBS or a PBS solution containing 1 mg of the shedding microvesicles derived from wild-type E. coli or the mutant E. coli transformed to have reduced lipopolysaccharide toxicity was injected at a dose of 100 mL twice a week via the tail vein into the mice which were divided into groups of three. On day 23 after the transplantation of cancer cells, the sizes of colon cancer tissue were monitored. The volume of cancer tissue was calculated by the equation V=l x s2/2, wherein 1 is a length of the longest axis of a tumor and s is a length of the axis perpendicular to the longest axis.
- After the subcutaneous transplantation, the volume measurements of colon cancer tissues were as shown in
FIG. 7 . As can be seen inFIG. 7 , the mouse group, when administered with the shedding microvesicles derived from the mutant E. coli which had been transformed to have reduced LPS toxicity, was observed to have a significantly decrease in tumor size, compared to the control administered with PBS only. Also, the colon cancer of the mutant group was much smaller in size than that of the wild-type group. - The following experiment was carried out with shedding microvesicles which were obtained in the same manner as in Example 3, with the exception that S. aureus coli transformed to have reduced toxicity of lipoteichoic acid (LTA mutant) was employed.
- A mouse colon 26 cell line was subcutaneously injected at a dose of 1 × 106 cells into mice, and cultured. After one week, PBS or a PBS solution containing 10 µg of the shedding microvesicles derived from wild-type S. aureus or the mutant S. aureus transformed to have reduced toxicity of lipoteichoic acid was injected at a dose of 100 µL twice a week via the tail vein into the mice which were divided into groups, each consisting of three. On day 23 after the transplantation of cancer cells, the sizes of colon cancer tissue were monitored. The volume of cancer tissue was calculated by the equation V=l x s2/2, wherein 1 is a length of the longest axis of a tumor and s is a length of the axis perpendicular to the longest axis.
- After the subcutaneous transplantation, the volume measurements of colon cancer tissues were as shown in
FIG. 8 . As can be seen inFIG. 8 , the mouse group, when administered with the shedding microvesicles derived from the mutant S. aureus which had been transformed to have reduced toxicity of lipoteichoic acid, was observed to significantly decrease in tumor size, compared to the control administered with PBS only. Also, the colon cancer of the mutant group was much smaller in size than that of the wild-type group. - The following experiment was carried out with shedding microvesicles which were obtained in the same manner as in Example 2, with the exception that E. coli transformed to have reduced lipopolysaccharide toxicity was employed.
- The mouse melanoma cell line (B16BL6) was injected at a dose of 1×105 cells into mice via the tail vein and cultured. After three days, PBS, or PBS containing 1 µg of the shedding microvesicles derived from E. coli that had been transformed to have reduced LPS toxicity, was injected at a dose of 100 µl in a day for 10 days via the tail vein into mouse groups, each consisting of three mice. On day 14 after the injection of the melanoma cells, the lungs were excised from the mice to count melanoma colonies metastasized to the lung.
-
FIG. 9 is a graph showing numbers of melanoma colonies metastasized to the lung in each mouse group of three. As can be seen inFIG. 9 , the mice administered with the microvesicles derived from E. coli that had been transformed to have reduced LPS toxicity were found to have much fewer melanoma colonies metastasized to the lung, compared to the PBS control. - From several centuries ago, the role of inflammation in oncogenesis has been suggested. In recent years, intensive attention have been paid to the research result that inflammatory reactions resulting from VEGF/IL-6-mediated signaling, STAT3 (signal transducer and activator of transcription 3) signaling, and Th17 immune responses play an important role in the onset and progression of cancer. In addition, aspirin was reported to reduce colorectal cancer risk. The present inventors have recently found that aspirin suppresses Th17-mediated inflammation. In this example, the anticancer activity of bacterial cell-derived microvesicles was examined when they were co-administered together with a drug suppressive of Th17 immune responses. In this regard, shedding microvesicles derived from E. coli that had been transformed to have reduced LPS activity were obtained in the same manner as in Example 2, and administered in combination with aspirin, a drug suppressive of the immune response of Th17.
- A mouse colon 26 cell line was subcutaneously injected at a dose of 1 × 106 cells into mice, and cultured. After one week, PBS, a PBS solution containing 18 mg/kg of aspirin, a PBS solution containing 0.1 µg of the bacterial cell-derived microvesicles, or a PBS solution containing 0.1 µg of the bacterial cell-derived microvesicles and 18 mg/kg of aspirin was injected at a dose of 100 µL twice a week via the tail vein into mouse groups, each consisting of four. On day 23 after the transplantation of cancer cells, the sizes of colon cancer tissue were monitored. The volume of cancer tissue was calculated by the equation V=l x s2/2, wherein l is a length of the longest axis of a tumor and s is a length of the axis perpendicular to the longest axis.
- After the subcutaneous transplantation, the volume measurements of colon cancer tissues were as shown in
FIG. 10 . As can be seen inFIG. 10 , there was no differences in the size of colon tumors between the group administered with aspirin alone and the control group administered with PBS alone. That is, the anticancer effect of aspirin was not observed. However, the size of colon tumors was significantly further reduced when the shedding microvesicles derived from E. coli that had been transformed to have reduced LPS toxicity were administered in combination with aspirin than alone. - Taken together, the data obtained above demonstrate that when co-administered together with a drug suppressive of the immune response of Th17, such as aspirin, the bacterial cell-derived shedding microvesicles suitable for use according to the present invention exerts greater anticancer activity.
- For use in the following experiments, shedding microvesicles derived from E. coli that had been transformed to have reduced LPS activity were obtained in the same manner as in Example 2.
- The shedding microvesicles were mixed at a ratio of 1:1 with 0.4 mg/ml of doxorubicin and incubated at 4°C for 12 hrs. Thereafter, the suspension was ultracentrifuged at 150,000 × g and 4°C for 3 hrs to separate shedding microvesicles from doxorubicin-loaded microvesicles. The doxorubicin-loaded microvesicles were incubated with DiO, a liphophilic trace with green fluorescence that can bind to cell membranes. DiO-labeled microvesicles were instilled on a cover glass, followed by observation under a confocal microscope to examine whether doxorubicin was loaded to the shedding microvesicles. The fluorescence images are given in
FIG. 11 . - As can be seen in
FIG. 11 , doxorubicin which appeared fluorescent red were loaded to the shedding microvesicles observed to be fluorescent green. From these results, it was understood that a therapeutic or diagnostic drug can be effectively loaded to bacterial cell-derived microvesicles. - Anticancer agent-loaded, bacterial cell-derived microvesicles were assayed for anticancer activity to examine whether the anticancer agent load has an influence on the activity of the microvesicles themselves. Doxorubicin was used as an anticancer agent.
- For use in the following experiments, shedding microvesicles derived from E. coli that had been transformed to have reduced LPS activity were obtained in the same manner as in Example 8.
- A mouse colon 26 cell line was seeded at a density of 5 × 104 cells into 24-well plates and cultured overnight. The cancer cells in each well were treated for 6 hrs with 1 mL of PBS or a PBS solution containing the bacterial cell-derived microvesicles loaded with or without doxorubicin, and then incubated for 18 hrs. Viable mouse colon cancer 26 cells were counted under a microscope, and the results are given in
FIG. 12 . - As can be seen in
FIG. 12 , doxorubicin-loaded, bacterial cell-derived microvesicles exerted greater inhibitory activity against cancer cells than did bacterial cell-derived microvesicles void of doxorubicin. - From this result, it is apparent that the anticancer activity of the anticancer drug-loaded, bacterial cell-derived microvesicles is contributed by not only the bacterial cell-derived microvesicles, but also by the loaded anticancer drug and thus is greater than that of the bacterial cell-derived microvesicles alone.
- In relation to the side effects of bacterial cell-derived microvesicles, Lipopolysaccharide, a component of bacterial cell-derived microvesicles, is known to play an important role one the onset of sepsis. Hence, an inhibitor of lipopolysaccharides that the microvesicles retain was examined for effects on the side effects of the microvesicles. In this experiment, polymyxin B was employed as an LPS inhibitor.
- E. coli-derived shedding microvesicles were constructed according to the method described in Example 2. PBS, a
PBS solution 25 µg of E. coli-derived shedding microvesicles, a PBS solution containing 25 µg of E. coli-derived shedding microvesicles plus 250 µg of polymyxin B were intraperitoneally injected at a dose of 100 µl into respective mouse groups, after which the survival rates of the mice were monitored at regular intervals of 12 hrs for 120 hrs. The results are given inFIG. 13 . - As can be seen in
FIG. 13 , the survival rate of the mice was 10 % at 120 hrs after administration with a PBS solution containing 25 µg of E. coli-derived shedding microvesicles, but increased to 55 % in the same period of time after administration with a PBS solution containing 25 µg of E. coli-derived shedding microvesicles plus 250 µg of polymyxin B. - From the result, it is understood that an inhibitory drug of the activity of lipopolysaccharides of E. coli-derived microvesicles effectively suppresses the side effects of the bacterial cell-derived microvesicles.
- The side effects of bacterial cell-derived microvesicles to which lipopolysaccharides, a component of Gram-negative bacterial cell-derived microvesicles, make contribution were examined using microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharide, a component of the microvesicles. In this experiment, the msbB mutant was employed as the E. coli transformed to have reduced toxicity of lipopolysaccharides.
- Shedding microvesicles were constructed in the same manner as in Example 2 from E. coli transformed to have reduced toxicity of lipopolysaccharides. PBS, a
PBS solution 25 µg of shedding microvesicles derived from wild-type E. coli, and a PBS solution containing 25 µg of shedding microvesicles derived from the mutant E. coli were intraperitoneally injected at a dose of 100 µl into respective mouse groups, after which the survival rates of the mice were monitored at regular intervals of 12 hrs for 120 hrs. The results are given inFIG. 14 . - As can be seen in
FIG. 14 , the survival rate of the mice was 45 % at 120 hrs after administration with a PBS solution containing 25 µg of the wild-type E. coli-derived shedding microvesicles, but increased to 65 % at the same period of time after administration with a PBS solution containing 25 µg of the mutant E. coli-derived shedding microvesicles. - From the result, it is understood that the side effects of bacterial cell-derived microvesicles can be effectively diminished when the microvesicles are derived from a mutant E. coli in which the activity of lipopolysaccharides is removed by modifying a gene responsible for the production of lipopolysaccharides, one of the microvesicle components causing the side effects, compared to when the microvesicles are derived from wild-type E. coli.
- In order to examine the side effects which might be generated upon the intravenous injection of bacterial cell-derived microvesicles, shedding microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides were employed. As indices for the side effects that might be generated upon intravenous injection, the number of platelets, blood coagulation, and hemolysis were examined.
- For use in this assay, shedding microvesicles were isolated in the same manner as in Example 2, from the E. coli transformed to have reduced toxicity of lipopolysaccharides.
- Mouse colon 26 cell line was subcutaneously injected at a dose of 1 x 106 cells into mice, and cultured. After one week, PBS or a PBS solution containing 5 µg of shedding microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides was injected via the tail vein into mouse groups, each consisting of two mice. After 3 or 6 hrs after, blood samples were taken from the mice.
- Platelets play an important role in the formation of blood clots. To examine the effect of the intravenous injection of bacterial cell-derived microvesicles on the number of platelets, the following experiment was carried out. The blood samples were 100-fold diluted in a dilution fluid (Rees-Ecker fluid), and incubated for 10 min at room temperature in a hemocytometer before counting platelets under an optical microscope. The results are given in
FIG. 15 . - Even when injected intravenously, as can be seen in
FIG. 15 , shedding microvesicles derived from E. coli that had been transformed to have reduced activity of lipopolysaccharides had no influences on platelets, which play an important role in blood coagulation. - D-dimer is a fibrin degradation product, a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis, and thus serves as a diagnostic criterion for disseminated intravascular coagulation. To examine the intravascular coagulation caused by the shedding microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides, the following experiment was carried out. The blood samples taken from Example 12 were centrifuged 1,300 x g for 10 min. The blood plasma thus obtained was 3-fold diluted and plated into 96-well plates coated with a capture antibody recognizing D-dimer. Then, a hydrogen peroxidase-conjugated detection antibody specific for D-dimer was added. Afterwards, a color was developed with the substrate BM-POD, and the results are given in
FIG. 16 . - Even when injected intravenously, as can be seen in
FIG. 16 , shedding microvesicles derived from E. coli that had been transformed to have reduced activity of lipopolysaccharides did not activate the coagulation mechanism. - The hemolysis caused by the shedding microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides was examined in the following experiment. PBS, and a PBS solution containing 1 µg/ml or 2 µg/ml of the mutant E. coli-derived shedding microvesicles were dropwise added in an amount of 10 µl to a blood agar plate, and incubated for 12 hrs at 37°C. The results are shown in
FIG. 17 . - As shown in
FIG. 17 , the shedding microvesicles derived from the E. coli that had been transformed to have reduced toxicity of lipopolysaccharides cannot destroy erythrocytes. - As is apparent from data of
FIGS. 15 to 17 , the shedding microvesicles derived from E. coli that that had been transformed to have reduced toxicity of lipopolysaccharides do not cause, even when injected intravenously, a decrease in the number of platelets, blood coagulation, and hemolysis. Therefore, the side effects of bacterial cell-derived microvesicles can be effectively reduced when the bacteria have been transformed to have reduced toxicity of lipopolysaccharides. - Lipoteichoic acid is known to induce inflammation through specific immune responses, and thus contributes to the side effects of Gram-positive bacterial cell-derived microvesicles because it is a component of the cell wall of Gram-positive bacteria. Hence, microvesicles derived from bacteria that had been transformed to lack a gene involved in the biosynthesis of lipoteichoic acid were used to evaluate the role of lipoteichoic acid in the side effects of Gram-positive bacterial cell-derived microvesicles. In this experiment, the LTA mutant was employed as the S. aureus transformed to remove lipoteichoic acid from the cell wall.
- Shedding microvesicles were constructed in the same manner as in Example 3 from S. aureus transformed to have reduced toxicity of lipoteichoic acid. After being isolated from the abdominal cavity of mice, macrophages (2.5 x 105 cells) were incubated for 12 hrs with 0.5 mL of each of PBS, a PBS containing 0.1 µg/ml of wild-type S. aureus-derived shedding microvesicles, and a PBS solution containing 0.1 µg/ml of the mutant S. aureus-derived shedding microvesicles, and the conditioned media were centrifuged at 500 x g for 5 min.
- Each well of 96-well plates coated with an IL-6 capture antibody was blocked for 1 hr with 100 µl of 1 % BSA (bovine serum albumin). The conditioned media was diluted by half, added to the plates, and incubated at room temperature for 2 hours and then for an additional 2 hrs in the presence of a biotinylated detection antibody against IL-6. The plates were washed with 1 % BSA, and incubated for 30 min with streptavidin-POD, followed by developing a color with the substrate BM-POD. The results are given in
FIG. 18 . - As is apparent from the data of
FIG. 18 , the level of IL-6 was reduced when shedding microvesicles derived from S. aureus that had been transformed to have reduced toxicity of lipoteichoic acid were administered, compared to wild-type S. aureus-derived shedding microvesicles. - From the result, it is understood that the side effects of bacterial cell-derived microvesicles can be effectively diminished when the microvesicles are derived from mutant bacteria in which the activity of lipoteichoic acid is reduced by modifying a gene responsible for the production of lipoteichoic acid, one of the microvesicle components causing the side effects, compared to when the microvesicles are derived from the wild-type.
- Important among the side effects of bacterial cell-derived microvesicles are a microvesicle-triggered immune response that induces the release of inflammatory mediators, causing topical or systemic inflammatory responses, and a microvesicle-caused coagulation that leads to thromboembolism or disseminated intravascular coagulation. In this experiment, aspirin was employed as an anti-inflammatory and anti-coagulant drug with the aim of reducing the side effects of bacterial cell-derived microvesicles.
- A mouse colon 26 cell line was subcutaneously injected at a dose of 1 x 106 cells into mice, and cultured. Shedding microvesicles were isolated in the same manner as in Example 2 from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides. After one week, PBS, a PBS solution containing 18 mg/kg of aspirin, a PBS solution containing 0.1 µg of the bacterial cell-derived microvesicles, and a PBS solution containing 0.1 µg of the bacterial cell-derived microvesicles plus 18 mg/kg of aspirin were injected at a dose of 100 µl via the tail vein into respective groups of four twice a week. Six hrs after the fifth injection, 0.2 ml of a blood sample was taken from the eye of each mouse, and placed in an anticoagulant tube containing 50 mM EDTA (ethylenediaminetetraacetic acid). Of the blood sample, 10 µl was mixed with 90 µl of 1 % HCl, and stored at room temperature for 7 min. White blood cells, indicative of systemic inflammation, in 10 µl of the mixture were counted using a hematocytometer. The result is given in
FIG. 19 . - As can be seen in
FIG. 19 , there were no differences in the level of white blood cells between the groups administered with aspirin alone and the group administered with PBS. The administration of the microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides reduced the level of white blood cells. However, the level of white blood cells returned to normal when aspirin was administered in combination with the microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides. - From the result, it is understood that co-administration of bacterial cell-derived microvesicles and an anti-inflammatory and/or anti-coagulant drug can effectively reduce the side effect (leucopenia) of bacterial cell-derived microvesicles.
- In this experiment, shedding microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides, prepared in the same manner as in Example 2, were examined for ability to deliver not only drugs, but also drug-associated carriers of various sizes.
- A mouse colon 26 cell line was subcutaneously injected at a dose of 1 x 106 cells into mice, and cultured for one week. PBS or a PBS solution containing 5 µg of shedding microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides was intravenously injected at a dose of 100 µl. After six hrs, 100 nm-sized green fluorescent beads were also intravenously injected, and allowed to sufficiently circulate through the body for 5 min. Thereafter, all the blood of the mice was substituted by PBS to remove fluorescent beads from blood vessels. Colon cancer tissues were excised, and cryosectioned at a thickness of 20 µm, followed by staining nuclei with 10 µg/ml of Hoechst dye. Fluorescent beads present within cancer tissues were observed under a confocal microscope. The results are given in
FIG. 20 . - When the shedding microvesicles derived from E. coli that had been transformed to have reduced toxicity of lipopolysaccharides were injected, as shown in
FIG. 20 , 100-nm sized fluorescent beads were observed to exist within the cancer tissue. In contrast, PBS did not allowed the fluorescent beads to target the cancer tissue. - From these results, it can be inferred that the administration of bacterial cell-derived microvesicles leads to more effective delivery of a subsequently injected anticancer drug or anticancer drug-loaded carrier in a size of tens to hundreds nanometers to a cancer tissue.
- According to the proteomic analysis of the present inventors, OmpA, one of the most abundant outer membrane proteins of Gram-negative bacteria, was most abundantly found in shedding microvesicles. Thus, in order to examine whether OmpA functions to mediate the anticancer activity of bacterial cell-derived microvesicles, OmpA was assayed for anticancer activity.
- A mouse colon 26 cell line was subcutaneously injected at a dose of 1 x 106 cells into mice, and cultured. After one week, PBS and a PBS solution containing 1 mg of a recombinant OmpA protein were injected at a dose of 100 µl twice a week via the tail vein into respective mouse groups of four. On day 21 after the transplantation of cancer cells, the sizes of colon cancer tissue were monitored. The volume of cancer tissue was calculated by the equation V=l x s2/2, wherein l is a length of the longest axis of a tumor and s is a length of the axis perpendicular to the longest axis. The measurement results are given in
FIG. 21 . - As can be seen in
FIG. 21 , a significant reduction in the size of colon cancer tissues was obtained after the recombinant OmpA protein was administered, compared to the control. This result demonstrates that OmpA present in the outer membrane of bacterial cell-derived shedding microvesicles is a factor functioning to mediate the anticancer activity of bacterial cell-derived microvesicles. - In addition to OmpA, the outer membrane protein OmpF was also found to be a major component of bacterial cell-derived shedding microvesicles according to the proteomic analysis result of the present inventors. Thus, OmpF-induced anticancer activity of bacterial cell-derived shedding microvesicles was assayed.
- In this regard, shedding microvesicles were obtained in the same manner as in Example 2, with the exception that OmpF-devoid E. coli was employed.
- A mouse colon 26 cell line was subcutaneously injected at a dose of 1 x 106 cells into mice, and cultured. After one week, PBS, a PBS solution containing 1 µg of wild-type E. coli-derived shedding microvesicles, and a PBS solution containing 1 µg of shedding microvesicles derived from OmpF-devoide E. coli were injected at a dose of 100 µl twice a week via the tail vein into respective mouse groups. On day 21 after the transplantation of cancer cells, the sizes of colon cancer tissue were monitored. The volume of cancer tissue was calculated by the equation V=l x s2/2, wherein l is a length of the longest axis of a tumor and s is a length of the axis perpendicular to the longest axis. The measurement results are given in
FIG. 22 . - As can be seen in
FIG. 22 , the anticancer activity of the shedding microvesicles derived from OmpF-devoid E. coli was lower than that of the shedding microvesicles derived from wild-type E. coli. - This result demonstrates that together with OmpA, OmpF present in the outer membrane of bacterial cell-derived shedding microvesicles functions as a factor responsible for the anticancer activity of bacterial cell-derived microvesicles.
- To construct liposomes, N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3 phosphoethanolamine sodium salt (MPEG-DSPE), fully hydrogenated soy phosphatidylcholine (HSPC), and cholesterol were separately dissolved in a concentration of 3.19 mg/mL, 9.58 mg/mL, and 3.19 mg/mL, respectively, in chloroform, and the three lipid solutions were mixed at a ratio of 1:1:1. Then, chloroform was removed using nitrogen gas to form a thin film. Urea buffer (344 mM urea, 10 mM KCl, 10 mM HEPES (pH 7.0, 3 mM NaN3) was added to this thin film, followed by ultrasonication at 56°C for 1 hr in a water bath sonicator. The resulting suspension was forced to pass five times through a membrane filter with a pore size of 1 µm, then five times through a membrane filter with a pore size of 400 nm, and finally five times through a membrane filter with a pore size of 100 nm to afford liposomes.
- To 0.3 ml of the liposomes was added 0.7 ml of urea buffer containing 280 µg of OmpA, followed by octyl-β-D-glucopyranoside to the final concentration of 1.1 %. After incubation at 37°C for 2 hrs, 15 ml of urea buffer was added. The resulting solution was ultracentrifuged at 100,000 x g for 1 hr. The pellet was suspended in 0.2 ml of urea buffer, and added to 50 % OptiPrep solution to form a final concentration of 30 %. In a 5 ml ultracentrifuge tube, 2 ml of the 30% liposome suspension, 1 ml of 20 % OptiPrep, and 1 ml of 5 % OptiPrep were placed in that order. Ultracentrifugation at 100,000 x g for 2 hrs formed an OmpA-loaded liposome layer between the 20 % OptiPrep layer and the 5 % OptiPrep layer.
- After 200 ng of OmpA and 5 µg of the OmpA-loaded liposomes were separately mixed with 5x loading dye, the mixtures were boiled at 100°C for 5 min, and loaded to 12 % polyacrylamide gel. Electrophoresis was performed at 80 V for 2 hrs, after which proteins were transferred onto a PVDF membrane at 400 mA for 2 hrs. The membrane was blocked at room temperature in 3 % skim milk in PBS, incubated with an OmpA antibody at 4°C for 12 hrs, and washed twice with PBS. Following incubation with a peroxidase-conjugated secondary antibody at room temperature for 1 hr, the membrane was washed for 30 min in PBS, and subjected to color development with an ECL substrate. The result is given in
FIG. 23 . - As can be seen in
FIG. 23 , OmpA was found to be loaded to liposomes. The OmpA protein, when isolated, is in a denatured form because it exists together with a detergent. However, when reconstituted into liposomes, OmpA is found to exist as both folded and denatured forms. From the result, it is understood that OmpA can be reconstituted into liposomes. - As described hitherto, the bacterial cell-derived microvesicles for use according to the present invention can specifically deliver substances therapeutic for cancer to cells or tissues of interest, thereby increasing therapeutic efficacy.
- Moreover, the bacterial cell-derived microvesicles with therapeutic and/or diagnostic substances loaded thereto and the preparation method thereof in accordance with the present disclosure may be used for in vitro and/or in vivo treatment, diagnosis or experiments.
Claims (13)
- Bacterial cell-derived spontaneously shedding microvesicles for use in the treatment of cancer, wherein(a) the microvesicles are administered simultaneously or sequentially with a drug that is suppressive of the toxicity of endotoxin of the microvesicles;(b) the microvesicles are loaded with a drug that is suppressive of the toxicity of endotoxin of the microvesicles; and/or(c) the bacteria are transformed to have a modified gene involved in formation of an endotoxin so that the microvesicles are mitigated in toxicity.
- The microvesicles for use of claim 1, wherein the microvesicles are administered simultaneously or sequentially with a drug that is suppressive of the toxicity of endotoxin of the microvesicles.
- The microvesicles for use of claim 1 or claim 2, wherein the microvesicles are loaded with a drug that is suppressive of the toxicity of endotoxin of the microvesicles.
- The microvesicles for use of any one of claims 1-3, wherein the bacteria are transformed to have a modified gene involved in formation of an endotoxin so that the microvesicles are mitigated in toxicity of endotoxin.
- The microvesicles for use of claim 2 or claim 3, wherein the bacteria are those that are naturally existing.
- The microvesicles for use of claim 1, wherein the bacteria express a substance therapeutic for cancer or are transformed to express the substance.
- The microvesicles for use of any of claims 1-6, wherein the drug suppressive of toxicity of endotoxin caused by the microvesicles is aspirin or polymyxin B.
- The microvesicles for use of any of claims 1 to 7, administered with a drug enhancing anticancer activity.
- The microvesicles for of use claim 8, wherein the drug enhancing anticancer activity is selected from a group consisting of aspirin, a drug suppressing Th17 (T helper 17 cell)-mediated immune responses, a drug suppressing formation or activity of interleukin-6, a drug suppressing angiogenesis, a drug suppressing formation or activity of vascular endothelial growth factor, a drug suppressing vascular endothelial growth factor receptor-mediated signaling, a drug suppressing STAT3 (Signal transducer and activator of transcription) signaling, and an anticancer agent.
- The microvesicles for use of any of claims 1 to 9, wherein the microvesicles are loaded with a drug for cancer therapy.
- The microvesicles for use of claim 10 wherein the microvesicles loaded with a drug for cancer therapy are derived from bacteria which have been transformed to target a cancer cell or tissue.
- The microvesicles for use of any of claims 1 to 11, wherein the microvesicles are derived from Gram-positive bacteria.
- The microvesicles for use of any of claims 1 to 11, wherein the microvesicles are derived from Gram-negative bacteria.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100063637 | 2010-07-01 | ||
KR1020110065151A KR101752506B1 (en) | 2010-07-01 | 2011-06-30 | Method for treatment and diagnosis of cancer using microvesicles derived from bacteria |
PCT/KR2011/004821 WO2012002760A2 (en) | 2010-07-01 | 2011-06-30 | Method for treating and diagnosing cancer by using cell-derived microvesicles |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2589391A2 EP2589391A2 (en) | 2013-05-08 |
EP2589391A4 EP2589391A4 (en) | 2014-03-05 |
EP2589391B1 true EP2589391B1 (en) | 2018-11-14 |
Family
ID=45402592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11801165.9A Active EP2589391B1 (en) | 2010-07-01 | 2011-06-30 | Bacterial cell-derived microvesicles for use in a method of treating cancer |
Country Status (6)
Country | Link |
---|---|
US (1) | US9066971B2 (en) |
EP (1) | EP2589391B1 (en) |
JP (1) | JP5635690B2 (en) |
KR (1) | KR101752506B1 (en) |
CN (1) | CN103079592B (en) |
WO (1) | WO2012002760A2 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012045082A2 (en) | 2010-10-01 | 2012-04-05 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
DK2791160T3 (en) | 2011-12-16 | 2022-05-30 | Modernatx Inc | MODIFIED MRNA COMPOSITIONS |
KR101373898B1 (en) * | 2012-02-24 | 2014-03-13 | 성균관대학교산학협력단 | In vivo imaging system using novel fluorescence-intercalated nucleic acid structure-based nanobarcodes, preparation method thereof, and uses thereof |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
DE18200782T1 (en) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
HRP20220607T1 (en) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminally modified rna |
PT2972193T (en) | 2013-03-13 | 2020-04-23 | Univ Miami | Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CN105283553B (en) | 2013-06-11 | 2021-06-25 | 克隆技术实验室有限公司 | Protein-enriched microvesicles and methods of making and using same |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US10561610B2 (en) | 2014-01-21 | 2020-02-18 | Anjarium Biosciences Ag | Hybridosomes, compositions comprising the same, processes for their production and uses thereof |
GB201420222D0 (en) * | 2014-11-13 | 2014-12-31 | Univ Edinburgh | Molecular probes and methods using the same |
KR20160110232A (en) * | 2015-03-11 | 2016-09-21 | 주식회사 엠디헬스케어 | Composition for Prevention or Treatment of Inflammatory disease Comprising Extracellular Vesicles Derived from Lactic acid bacteria |
KR101745455B1 (en) * | 2015-03-24 | 2017-06-09 | 포항공과대학교 산학협력단 | Multistage purification method of extracellular vesicles by aqueous two-phase system |
CN104888230A (en) * | 2015-05-28 | 2015-09-09 | 杭州优玛达生物科技有限公司 | Application of biological membrane obtained by natural source and/or self-assembly technology, and closed structure or cellular compartment with biological membrane property as medicine carriers |
CN104922685A (en) * | 2015-05-28 | 2015-09-23 | 杭州优玛达生物科技有限公司 | Application of naturally-sourced and/or self-assembled biological membrane, closed structure or cell compartment with biological membrane property as medical high polymer material |
WO2017044940A1 (en) * | 2015-09-10 | 2017-03-16 | Washington State University | Cell membrane-formed nanoscale vesicles and methods of using thereof |
SI3350157T1 (en) | 2015-09-17 | 2022-04-29 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
DK3386484T3 (en) | 2015-12-10 | 2022-07-04 | Modernatx Inc | COMPOSITIONS AND METHODS OF DELIVERING THERAPY PRODUCTS |
JP7114465B2 (en) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | Compounds and compositions for intracellular delivery of drugs |
KR102085787B1 (en) * | 2016-08-12 | 2020-03-06 | 주식회사 엠디헬스케어 | Nanovesicles derived from Bacillus bacteria and Use thereof |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
CN106692984B (en) * | 2016-12-08 | 2020-02-18 | 武汉大学 | Tumor targeted delivery carrier based on cell-derived microvesicles, and preparation method and application thereof |
JP7332478B2 (en) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | Lipid nanoparticle formulation |
EP4186888A1 (en) | 2017-03-15 | 2023-05-31 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
CA3056133A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
KR102109950B1 (en) * | 2017-06-02 | 2020-05-12 | (주)엑솔런스바이오테크놀로지 | Delivery method of target material into extracellular vesicles using extracorporeal shock wave |
US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
JP2019017297A (en) * | 2017-07-17 | 2019-02-07 | 杭州優瑪達生物科技有限公司Hangzhou UMotor Biotech Co., LTD. | Biomembrane, closed structure with biomembrane characteristics, or cellular compartment derived from natural sources and/or self-assembly techniques, preparation method therefor, and applications thereof |
TWI814739B (en) * | 2017-09-08 | 2023-09-11 | 美商艾弗洛生物科技股份有限公司 | Bacterial extracellular vesicles |
WO2019051381A1 (en) * | 2017-09-08 | 2019-03-14 | Evelo Biosciences, Inc. | Extracellular vesicles from prevotella |
KR102282490B1 (en) * | 2018-01-12 | 2021-07-28 | 주식회사 엠디헬스케어 | Nanovesicles derived from Faecalibacterium prausnitzii and Use thereof |
KR102101692B1 (en) * | 2018-03-05 | 2020-04-20 | 주식회사 엠디헬스케어 | Nanovesicles derived from Lactobacillus bacteria and Use thereof |
WO2019182372A1 (en) * | 2018-03-21 | 2019-09-26 | ㈜로제타엑소좀 | Bacterial extracellular vesicles having reduced toxicity and use thereof |
US20210205379A1 (en) * | 2018-05-30 | 2021-07-08 | University Of Florida Research Foundation, Incorporated | Mechanistic bacterial efector to prevent apoptosis of human beta cells |
WO2020006216A1 (en) * | 2018-06-27 | 2020-01-02 | Evelo Biosciences, Inc. | Compositions and methods of treating cancer using neisseria bacteria |
US20210338583A1 (en) * | 2018-07-23 | 2021-11-04 | Robert B. Campbell | Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy |
KR102098067B1 (en) * | 2018-12-31 | 2020-04-07 | 주식회사 엠디헬스케어 | Extracellular vesicle derived from Lactobacillus paracasei and use thereof |
WO2020145663A1 (en) * | 2019-01-09 | 2020-07-16 | 주식회사 엠디헬스케어 | Nanovesicles derived from bacteria of genus rhodococcus, and use thereof |
KR102211721B1 (en) * | 2019-02-11 | 2021-02-04 | 경북대학교 산학협력단 | Medicament carrier for permeation of a blood-brain barrier comprising bacterial-derived cell outer membrane vesicles |
CA3136978A1 (en) * | 2019-04-17 | 2020-10-22 | Biogaia Ab | Therapeutic microvesicles of probiotic bacteria |
US11066355B2 (en) | 2019-09-19 | 2021-07-20 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
KR102329816B1 (en) | 2020-03-20 | 2021-11-19 | 인천대학교 산학협력단 | A Method for Separating and Concentrating Cells or Secretion thereof using Super Absorbent Beads |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
KR102413278B1 (en) | 2021-06-21 | 2022-06-27 | (주)로제타엑소좀 | Commercially efficient method for purifying bacterial extracellular vesicles in high purity |
WO2023211207A1 (en) * | 2022-04-28 | 2023-11-02 | (주)아이엠지티 | Focused ultrasound treatment apparatus operating in conjunction with nanodrug carrier, ultrasound control method, and nanodrug carrier thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD273198A5 (en) * | 1986-06-09 | 1989-11-08 | �������@�������k���Kk�� | METHOD FOR PRODUCING A MODIFYING AGENT |
AU7477791A (en) * | 1990-03-02 | 1991-09-18 | Joaquin J. Jimenez | Method for treating cancer using combination chemotherapy and brm |
JP3769057B2 (en) | 1994-11-17 | 2006-04-19 | 麒麟麦酒株式会社 | Method for producing microcapsules |
US20020028215A1 (en) * | 1999-08-09 | 2002-03-07 | Jagath L. Kadurugamuwa | Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same |
JPH1076155A (en) | 1996-09-02 | 1998-03-24 | Kirin Brewery Co Ltd | Microcapsule containing fat-insoluble substance and its production |
DE10003241A1 (en) | 2000-01-26 | 2001-08-02 | Werner Lubitz | Sealing bacterial ghosts |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
JP4592547B2 (en) * | 2005-08-24 | 2010-12-01 | 株式会社エヌ・ティ・ティ・ドコモ | Transmission power control method and mobile communication system |
WO2007047501A2 (en) * | 2005-10-14 | 2007-04-26 | George Mason University | Outer membrane vesicles: novel vaccine for gram-negative biothreat agents |
CA2652475A1 (en) * | 2006-05-12 | 2007-11-22 | National University Corporation Hokkaido University | Liposome having lipid membrane containing bacterial cell component |
US20100035234A1 (en) * | 2008-05-19 | 2010-02-11 | Novartis Ag | Vaccine assays |
KR101042541B1 (en) * | 2008-07-25 | 2011-06-17 | 한국생명공학연구원 | Recombinant Gram-negative Bacteria Producing Outer Membrane Vesicles and Method for Preparing Outer Membrane Vesicles Tagged with Foreign Epitopes Using the Same |
-
2011
- 2011-06-30 CN CN201180041981.9A patent/CN103079592B/en active Active
- 2011-06-30 JP JP2013518259A patent/JP5635690B2/en active Active
- 2011-06-30 US US13/807,843 patent/US9066971B2/en active Active
- 2011-06-30 KR KR1020110065151A patent/KR101752506B1/en active IP Right Grant
- 2011-06-30 WO PCT/KR2011/004821 patent/WO2012002760A2/en active Application Filing
- 2011-06-30 EP EP11801165.9A patent/EP2589391B1/en active Active
Non-Patent Citations (2)
Title |
---|
JESSICA I. LUNDIN ET AL: "Endotoxin and Cancer", ENVIRONMENTAL HEALTH PERSPECTIVES SUPPLEMENTS, vol. 117, no. 9, 1 September 2009 (2009-09-01), US, pages 1344 - 1350, XP055221367, ISSN: 1078-0475, DOI: 10.1289/ehp.0800439 * |
KIM S H ET AL: "Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - BIOMEMBRANES, ELSEVIER, AMSTERDAM, NL, vol. 1788, no. 10, 1 October 2009 (2009-10-01), pages 2150 - 2159, XP026684863, ISSN: 0005-2736, [retrieved on 20090818], DOI: 10.1016/J.BBAMEM.2009.08.001 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012002760A2 (en) | 2012-01-05 |
KR20120002943A (en) | 2012-01-09 |
KR101752506B1 (en) | 2017-06-30 |
CN103079592B (en) | 2015-10-21 |
EP2589391A2 (en) | 2013-05-08 |
US9066971B2 (en) | 2015-06-30 |
CN103079592A (en) | 2013-05-01 |
US20130195765A1 (en) | 2013-08-01 |
JP2013530216A (en) | 2013-07-25 |
WO2012002760A3 (en) | 2012-05-03 |
JP5635690B2 (en) | 2014-12-03 |
EP2589391A4 (en) | 2014-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2589391B1 (en) | Bacterial cell-derived microvesicles for use in a method of treating cancer | |
US9084830B2 (en) | Microvesicles derived from cell protoplast and use thereof | |
US20210212948A1 (en) | Nanovesicles derived from cell membrane, and use thereof | |
US10675244B2 (en) | Microvesicles derived from nucleated, mammalian cells and use thereof | |
CN117159470A (en) | Liposome encapsulated affinity drug | |
CN113694075A (en) | Use of exosomes for treating diseases | |
KR102212335B1 (en) | toxic-reduced extracellular vesicles derived from bacteria and use thereof | |
US20180177725A1 (en) | Cell membrane-formed nanoscale vesicles and methods of using thereof | |
CN110711182A (en) | Surface-modified microorganism, and preparation method and application thereof | |
KR20170104024A (en) | Nanovesicles derived from Helicobacter pylori and Use thereof | |
D'Urso | Magnetic nanoparticles as nanocarriers and immune modulators for cancer targeted therapy | |
CN115919797A (en) | Application of exosome-loaded adriamycin in treatment of neuroblastoma | |
Voicu et al. | Materials Today Bio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130130 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KIM, YOON KEUN Inventor name: GHO, YONG SONG Inventor name: YOON, CHANG MIN Inventor name: KIM, OH YOUN Inventor name: JANG, SU CHUL |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20140203 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 49/08 20060101ALI20140128BHEP Ipc: A61K 9/133 20060101ALI20140128BHEP Ipc: A61K 47/48 20060101ALI20140128BHEP Ipc: A61P 35/00 20060101ALI20140128BHEP Ipc: A61K 39/085 20060101AFI20140128BHEP |
|
17Q | First examination report despatched |
Effective date: 20160212 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: EXOSOME BIOSCIENCE CO., LTD. |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602011053932 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0039085000 Ipc: A61K0035740000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20180328BHEP Ipc: A61K 47/69 20170101ALI20180328BHEP Ipc: A61K 35/74 20060101AFI20180328BHEP Ipc: A61K 49/08 20060101ALI20180328BHEP Ipc: A61K 9/133 20060101ALI20180328BHEP Ipc: A61K 47/55 20170101ALI20180328BHEP Ipc: A61K 49/00 20060101ALI20180328BHEP Ipc: A61K 39/085 20060101ALI20180328BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180509 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ROSETTA EXOSOME CO., LTD. |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20181004 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1063999 Country of ref document: AT Kind code of ref document: T Effective date: 20181115 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011053932 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20181114 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1063999 Country of ref document: AT Kind code of ref document: T Effective date: 20181114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190214 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190314 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190214 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190215 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190314 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011053932 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20190815 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20110630 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181114 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20230701 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240322 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240408 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240320 Year of fee payment: 14 |